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By Maria Laura Amaya, B.S,
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Philosophy at Virginia Commonwealth University.
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Major Director: Gordon D. Ginder
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Professor, Departments of Internal Medicine, Human and Molecular Genetics and Microbiology
and Immunology

An understanding of the human fetal to adult hemoglobin switch offers the potential to
ameliorate β-type globin gene disorders such as sickle cell anemia and β-thalassemia through
activation of the fetal γ-globin gene. Chromatin modifying complexes, including MBD2-NuRD
and GATA-1/FOG-1/NuRD play a role in γ-globin gene silencing, and Mi2β (CHD4) is a critical
component of NuRD complexes. In the studies presented in Chapter 2, we observed that the
absence of MBD2 in a sickle cell mouse model leads to a decrease in the number of sickled cells
observed in the peripheral blood, and significantly increases survival in these mice. Although
further studies will be necessary to fully understand the effect of MBD2 knockout in sickle cell
disease mice, absence of MBD2 appears to partially ameliorate the sickle cell anemia phenotype
in vivo.
In the studies presented in Chapter 3, we observed that knockdown of Mi2β relieves γglobin gene silencing in β-YAC transgenic murine CID hematopoietic cells and in CD34+
progenitor derived human primary adult erythroid cells. We show that independent of MBD2-

xviii

NuRD and GATA-1/FOG-1/NuRD, Mi2β binds directly to and positively regulates both the
KLF1 and BCL11A genes, which encode transcription factors critical for γ-globin gene silencing
during β-type globin gene switching. Remarkably, less than 50% knockdown of Mi2β is
sufficient to significantly induce γ-globin gene expression without disrupting erythroid
differentiation of primary human CD34+ progenitors. These results indicate that Mi2β is a
potential target for therapeutic induction of fetal hemoglobin.
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Chapter 1. Introduction

I. Hemoglobin and the hemoglobin switch

A. Hemoglobin
Hemoglobin is the oxygen carrying metalloprotein in the body and the major component
of red blood cells. Its main function is to carry oxygen from the lungs to tissues. Although there
are different types of hemoglobin, each of them is a tetramer composed of four subunits
including two α-like chains and two β-like globin chains. In humans, the genes coding α-chains
are located on chromosome 16. The α-globin locus contains one functional embryonic ζ-globin
gene and two adult α-globin genes. The genes coding for the β globin chains are located on
chromosome 11, and they determine the type of hemoglobin produced at different stages of life.
The β-type globin genes include ε- (embryonic) γ- (fetal) δ- and β-globin (adult), each expressed
at their corresponding stage as named. The ε-globin gene is the most upstream gene in the βglobin locus and the first one expressed during embryogenesis. The γ-chains come from two
genes located in tandem, and their protein products only differ by one amino acid at position
γ136, where the upstream gene contains a glycine and the downstream gene contains an alanine,
G A

γ γ. The γ-globin genes are predominantly expressed in the fetal stages of development. The δ-

globin gene is a result of a duplication of the β-globin gene and its expression remains low
throughout postnatal life. The β-globin gene is the most downstream gene of the β-locus and β-
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globin chain synthesis predominates during adulthood (Nathan et al. 2003). All globin
chains are relatively small peptides of roughly 150 amino acids (~16kDa).
In human adults, the predominant hemoglobin (HbA) is composed two α- and two βglobin chains, and it comprises ~96-98% of total hemoglobin. HbA2, composed of two α- and
two δ-globin chains, comprises ~2.4% of total hemoglobin in adults. Fetal hemoglobin (HbF),
composed of two α- and two γ-globin chains, comprises <2% of total hemoglobin in adults
(Nathan et al. 2003).

B. The β-globin locus and the hemoglobin switch
In humans, the fetal γ-globin gene is located on the β-globin locus on chromosome 11. As
described in section A, this locus consists of a family of genes placed in the sequence they are
expressed during gestation and adulthood, and it is preceded by a locus control region (LCR-εγGγA-δ-β) (Stamatoyannopoulos 2005; Sankaran, Xu & Orkin 2010) (Figure 1). During the first 6
to 8 weeks of gestation or embryonic stage, ε-globin is highly expressed in the yolk sac and
paired with ζ-globin chains. This is followed by high expression of γ-globin in the liver during
most of gestation allowing 2 γ-globin chains to pair with 2 α-globin chains to form fetal
hemoglobin (HbF). At birth, γ-globin expression begins to decline as the expression of β-globin
increases in the bone marrow (Boyer et al. 1975; Peschle et al. 1985; Ley et al. 1989) (Figure 1).
At this stage, 2 β-globin chains pair with 2 α-globin chains to form adult hemoglobin (HbA).
This process if often referred to as the “hemoglobin switch” since it describes the “switch” that
occurs between fetal γ-globin and adult β-globin expression.
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and the genetics underlying part of this variation has been
increased (Peschle et al, 1985; Ley et al, 1989). Over the course
discussed in a recent review in this journal (Thein & Menzel,
of gestation, the major b-like haemoglobin subunit that is
2009). The nature of this switch will be discussed in further
expressed is c-globin. c-Globin is assembled with the adult
detail later in this review.
a-globin subunits to form the fetal haemoglobin (HbF)
Haemoglobin switching of both the primitive to definitive
tetramer (a2c2). During primate evolution, the genes encoding
and the fetal to adult types has been studied as models for the
the fetal haemoglobin subunit were duplicated, such that there
developmental control of gene expression. The b-globin loci of
are two fetal globin genes in humans, HBG1 (Ac) and HBG2
mammals were among the first gene loci to be cloned and
(Gc), which differ by only a single amino acid. As the newborn
sequenced, and have constituted an important model system
period approaches, the fetal switch begins to take place from
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The mouse globin locus greatly resembles the human β-locus. Mice have two embryonic
globin genes (εy and βh1) and two adult globin genes (βmaj and βmin), but unlike humans they
do not have fetal globin genes (Figure 1). Embryonic genes (εy and βh1) are mostly expressed in
primitive (embryonic) erythroid cells and βmaj and βmin are strictly expressed in definitive
(adult) erythroid cells (Trimborn et al. 1999). A transition begins at around day E11.5 in
gestation when the definitive cells are first detected in the peripheral blood (Popp, D’Surney &
Wawrzyniak 1987). In mice, the hemoglobin switch therefore occurs at the embryonic stage as
depicted in Figure 1. In transgenic mice containing the human β-globin locus, the human fetal
globin genes (Aγ and Gγ) assume the regulation of the endogenous murine embryonic genes and
the hemoglobin switch occurs during gestation as depicted with dotted lines in Figure 1.

II. Erythrocytes and Erythropoiesis

A. Erythrocytes
Red blood cells, or erythrocytes, are oval cells characterized by being highly flexible, and
hemoglobin makes up the majority of their protein content. Unlike other cells of the human
body, erythrocytes lack a nucleus in order to accommodate a large amount of hemoglobin
molecules. Their life span is about 120 days (Alison 1960).

B. Erythropoiesis
Erythropoiesis is the process by which erythroid precursors differentiate to give rise to
mature erythroid cells. In humans there are two types of erythropoiesis, primitive (embryonic)
erythropoiesis, and definitive (adult) erythropoiesis. Early in ontogeny primitive erythropoiesis
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occurs in the yolk sac, where immature erythroid precursors are released into the bloodstream
where they mature and enucleate (Palis 2008). Definitive, or adult erythropoiesis occurs at later
stages of gestation in the fetal liver. Towards the last three months of gestation, definitive (adult)
erythroipoiesis moves to the bone marrow, where erythropoiesis continues through adulthood
(Palis 2008; Tsiftsoglou et al. 2009). Unlike primitive erythropoiesis where erythroid cells
mature in the bloodstream, definitive erythroipoiesis is characterized by “blood islands” in which
erythroid precursors are surrounded by macrophages and they enucleate before entering the
bloodstream (Palis 2008).
Erythrocytes differentiate through a series of stages in the bone marrow. Hematopoietic
stem cells differentiate into a common myeloid progenitor followed by early erythroid
progenitors (burst forming unit-erythroid and colony forming unit-erythroid). These give rise to
proerythroblasts, followed by differentiation of these cells in the following order: basophilic
erythroblast, polychromatic erythroblast, orthochromatic erythroblast, polychromatic erythrocyte
(or reticulocyte) to finally a mature erythrocyte (Figure 2). Although this terminology refers to
their appearance on a light microscope after Wright staining, each of these stages represents a
different step in differentiation and is marked by expression of different genes and cell surface
markers. During mammalian erythropoiesis, there is a significant decrease in cell size and
condensation of the nucleus until enucleation occurs at the orthochromatic erythroblast stage.
Reticulocytes are then released into the circulation (Handlin, Lux & Stossel 2002). Reticulocytes
contain abundant amount of RNA capable of specifying synthesis of hemoglobin. They comprise
~ 0.5-1.5% of erythrocytes and circulate in the bloodstream for about 1 day before fully maturing
into erythrocytes (Skadberg, Brun & Sandberg 2003).
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Erythropoiesis is a highly regulated process in terms of cell proliferation, and preventing
apoptosis and cell cycle arrest while approaching terminal differentiation. Changes in oxygen
tension, iron homeostasis, and stress can affect this process (Tsiftsoglou et al. 2009).

Figure 2. Stages of human erythropoiesis. In the bone marrow, hematopoiesis begins with
pluripotent hematopoietic stem cells (HSC). These cells give rise to a common myeloid
progenitor (CMP), followed by a megakaryocytic/erythroid pluripotent progenitor (MEP).
Erythropoiesis (highlighted in the diagram) occurs in the following order: Burst forming uniterythroid (BFU-E) gives rise to colony forming unit-erythroid (CFU-E), followed by
intermediate forms for Proerythroblasts (ProEB), which give rise to orthrochromatic normoblast
(ON). Enucleation occurs at the normoblast stage and reticulocytes (RET) are released into the
bloodstream where they eventually become mature red blood cells (RBCs). Adapted from
Tsiftsoglou, Vizirianakis & Strouboulis 2009.
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III. Hemoglobinopathies
Hemoglobinopathies such as sickle cell anemia and β-thalassemia result from among the
most common single gene defects worldwide and affect a significant amount of the population in
the United Stated. It is estimated that about 300,000 children worldwide are born each year with
either sickle cell anemia or thalassemia (Weatherall 2010). These genetic disorders result from
mutations that affect hemoglobin.

A. Sickle cell anemia.
Sickle cell anemia is an autosomal recessive disorder. The first sickle cell anemia patient
was described by James Herrick in 1910. In his report, he wrote “what especially attracted
attention was the large number of thin, elongated, sickle-shaped and crescent-shaped forms”
when describing a case of a patient with severe anemia (Herrik 1910). Sickle cell anemia was
first described as a molecular disease in 1949 (Pauling & Itano 1949), and it results from a point
mutation in the in the 6th position of the beta globin gene (A-to-T) that replaces a glutamic acid
for a valine (Ingram 1956). This recessive disorder is most prevalent in some regions of Africa,
where more than a quarter of the population carry the trait. The β-globin mutation became more
prevalent in parts of the world where it conferred a survival advantage against malaria caused by
Plasmodium falciparum, a parasite that infects erythrocytes (Livingstone 1958). It is also
prevalent in parts of Saudi Arabia, Greece, India and Brazil, and about 8% of African Americans
are also carriers (Steinberg 2008).
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i. Pathophysiology.
In sickle cell anemia, a point mutation in the β-globin gene causes a change from glutamic
acid to valine. This valine, a hydrophobic amino acid, is exposed when hemoglobin assumes its
deoxy conformation (under low oxygen conditions), and it clusters with hydrophobic pockets of
other β-chains causing polymerization of hemoglobin molecules as shown in Figure 3B (Nathan
et al. 2003). Polymers accumulate and contribute to an abnormally elongated shape in erythroid
cells, preventing their deformability. Although polymerization is a reversible process, the shape
change of erythroid cells is not always reversible. The lack of deformability of sickle-shaped
cells makes their passage through the microvasculature difficult, therefore causing vasoocclusion (Figure 3C). Adhesion of sickle cell anemia erythrocytes to the vascular endothelium
is also common, further contributing to vaso-occlusion (Ballas & Mohandas 1996; Nathan et al.
2003).
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Figure 3. Pathophysiology of sickle cell anemia. (A) The glutamic acid-to-valine mutation causes
valine hydrophobic residues to become exposed and cause a conformational change in the
hemoglobin tetramer under low oxygen conditions. (B) Hydrophobic interactions allow
hemoglobin molecules to form polymers. (C) Polymers lead to a shape change of red blood cells
that resembles a sickle. Sickle shaped erythrocytes cause occlusion in small vessels, resulting in
ischemia and pain crises. Adapted from carnegiescience.edu (A) evolution.berkeley.edu (B) and
www.nhlbi.nih.gov (C).
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ii. Clinical manifestations of sickle cell anemia.
Since polymer formation in carriers is very rare, heterozygote patients (also known as
sickle cell trait) do not usually show any symptoms. Nonetheless, clinical findings such as
urinary tract infections, hematuria and splenic infarct during strenuous exercise and low oxygen
conditions are possible (Sears 1978; Kark & Ward 1994).
Sickle cell anemia is largely characterized by chronic anemia. Vaso-occlusion caused by
abnormally sickle shaped erythrocytes obstructing small vessels is responsible for most of the
complications of this condition. Such complications include acute chest syndrome, strokes,
retinopathy, priapism, and chronic nephropathy. Hemolysis (lysis of erythrocytes) not only
contributes to severe anemia, but also to vaso-occlusive crisis through reduction of nitric oxide
availability (Nathan 2003).
Clinical manifestations can vary depending of the stage of life. In the early years of life,
the most common manifestations include painful episodes, acute chest syndrome and stroke.
Painful episodes are caused by vaso-occlusion and present as painful swelling of the hands and
feet. Acute chest syndrome is characterized by fever, chest pain, wheezing, cough, hypoxia, and
lung infiltrate. Later in life, chronic organ hypoxia leads to organ damage and failure. Renal
disease oftentimes leads to renal failure in older patients (Nathan et al. 2003; Steinberg 2008).
Loss of splenic function makes these patients more susceptible to bacterial infections, in
particular pneumococci. Pneumococcal vaccines are therefore standard prevention for patients
with sickle cell anemia. Acute chest syndrome is a common cause of death in adults with sickle
cell anemia (Nathan et al. 2003).
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B. β-thalassemia.
Severe β-thalassemia was first described by Thomas Cooley in 1925, when studying
Italian and Greek children with severe anemia. Aside from severe anemia, these children
exhibited hepatosplenomegaly, growth retardation and bone deformities. β-thalassemia major is
also termed Cooley’s anemia (Cooley & Lee 1925).
There are about 23,000 children born with β-thalassemia each year and it is most
prevalent in Mediterranean countries, the Middle East, India, North Africa and Central and
Southeast Asia (Weatherall 2010).

i. Pathophysiology
The β-thalassemias are a group of disorders that result form either absence or a reduction
in the expression of β-globin gene. Point mutations are the most common cause, although
deletions can also result in absence of β-globin gene expression (Higgs, Thein & Woods 2001).
Reduction or absence of β-globin chain synthesis results in an imbalance of the normal α-to-βglobin chain ratio, leading to accumulation of excess α chains. This abnormal ratio results in
ineffective erythropoiesis in the bone marrow (Figure 4) as well as hemolysis in the peripheral
blood. In the case of ineffective erythropoiesis, apoptosis of erythroid precursors (Yuan et al.
1993) is triggered by formation of hemichromes (α-globin chains/heme aggregates) (Figure 4). In
mature red blood cells, intravascular hemolysis is also caused by α-globin chains’ inability to
form tetramers and stay in solution. Excess α-globin chains therefore precipitate and the
hemichromes interact with cell membrane proteins such as spectrin, causing cell damage and
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hemolysis (Shinar , Rachmilewitz & Lux 1989).

medical progress

Figure 4. Ineffective erythropoiesis in β-thalassemia. In the bone marrow, excess α-chain
deposition (hemichromes) leads to apoptosis of erythroid precursor cells. Adapted from Rund &
Rachmilewitz 2005.

ii. Clinical Manifestations of β-thalassemia.
The clinical presentation of β-thalassemia patients can vary from no overt symptoms to
severe anemia depending on the type of mutation and the level of β-globin gene expression. βthalassemias can therefore be classified into 1) β-thalassemia trait in which only one copy of the
gene carries a mutation and patients show mild or no anemia. 2) β-thalassemia intermedia in
which both copies of the gene carry a mutation but at least one mutation is mild and results in
expression of β-globin gene. Patients show mild to moderate anemia and splenomegaly. 3) βthalassemia major in which both genes carry a severe mutation resulting in little or no expression
of the β-globin gene. Patients show severe anemia and are transfusion dependent (Rund &
Rachmilewitz 2005).
Aside from severe anemia, β-thalassemia patients can also present with
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hypercoagulability (Eldor & Rachmilewitz 2001), pulmonary hypertension (Morris & Vichinsky
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2011), bone expansion and extramedullary hematopoiesis. Patients who are transfusion
dependent are prone to suffer from further complications due to excess iron deposit in organs.
This is, in fact, the cause of most complications in patients with β-thalassemia. Although
chelating therapy has improved the negative effects of excess iron, its side effects result in poor
compliance. Most of the iron deposit occurs in the liver, heart and in endocrine glands. Chronic
anemia and iron overload in these patients often results in endocrinopathies and impaired growth.
Hypogonadism is also common (Cunningham et al. 2004; De Sanctis 2002; Raiola et al. 2003)
and it is treated with hormonal therapy. In older patients, bone disease (including osteopenia and
osteoporosis) is caused by bone expansion due to defective erythropoiesis as well as endocrine
deficiencies. Although iron deposit affects various organs including the liver resulting in
cirrhosis, and the pancreas resulting in diabetes mellitus, it has the most negative impact in the
heart, as cardiac events are the most common cause of death in these patients (Rund &
Rachmilewitz 2005).
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Figure 1. Management of Thalassemia and Treatment-Related Complications.
The anemia that is associated with thalassemia may be severe and is accompanied by ineffective erythropoiesis, with bone
expansion and extramedullary hematopoiesis in the liver, spleen, and other sites, such as paravertebral masses. Transfusion therapy, which is the mainstay of treatment, allows for normal growth and development and suppresses ineffective
erythropoiesis. Transfusion-transmitted infections (primarily hepatitis B and C) are an important cause of death in countries where proper testing is not available. Iron overload results both from transfusional hemosiderosis and excess gastrointestinal iron absorption. Iron deposition in the heart, liver, and multiple endocrine glands results in severe damage
to these organs, with variable endocrine organ failure. The endocrinopathies can be treated with hormone replacement.
However, the most serious result of iron overload is life-threatening cardiotoxicity, for which chelation therapy is required.
Thalassemia can be cured by bone marrow transplantation. Experimental therapies to ameliorate the anemia that have
been or are currently under investigation include fetal hemoglobin modifiers and antioxidants. In the future, gene therapy or other molecular methods may be feasible.

Figure 5. Clinical manifestations of β-thalassemia. Depicted above are some of the clinical
manifestations of β-thalassemia patients, which include bone expansion and organ damage due to
iron deposit. Organ damage leads to cirrhosis, diabetes mellitus, and cardiomyopathy. Current
therapy is mostly supportive, consisting of transfusions along with chelating agents, hormone
replacement and vitamin D. The only curative therapy is bone marrow transplantation. Adapted
from Rund & Rachmilewitz 2005.
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C. The role of fetal hemoglobin on β-type globin disorders
It was first observed that infants with sickle cell anemia did not develop symptoms until
several months after birth due to higher levels of fetal hemoglobin (HbF) during this period
(Watson 1948). The idea of high HbF conferring protection against sickle cell anemia was later
reinforced by the observation that West African sickle cell patients who co-inherited a condition
known as hereditary persistence of fetal hemoglobin (HPFH) were highly asymptomatic
(Edington & Lehmann 1955). HPFH is a benign condition in which high levels of HbF are
caused by either deletions or mutations. Thalassemia patients who co-inherited HPFH were also
noted to be asymptomatic (Jacob & Raper 1958).
The mechanism behind HbF’s protective role in sickle cell anemia became apparent years
later when HbF was shown to prevent polymer formation. In sickle cell anemia, the tetramer
α2βS2 forms polymers in its deoxygenated state. However, a hemoglobin molecule composed of
the hybrid tetramer α2βSβA (one normal β-chain and one mutated β-chain) has only half the
probability of polymerizing. Introducing one γ-globin chain forming a hybrid tetramer (α2βSγ)
does not allow hemoglobin polymerization and therefore prevents sickling (Steinberg 2009). It
was later demonstrated than an increase in HbF decreases mortality in sickle cell patients (Platt
et al.1994). Of note, the hybrid (α2βSδ) has also been shown to decrease the polymerization in a
similar manner as α2βSγ (Nagel et al.1979).
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D. The need for new treatments for sickle cell anemia and β-thalassemia patients
Early studies showed methylation plays an important role in the regulation of embryonic
and fetal β-type globin expression and therefore HbF production (Mavilio et al. 1983; McGhee &
Ginder 1979; Shen & Maniatis 1980; van der Ploeg & Flavell 1980). In attempts to find agents
that would lead to an increase in HbF in patients with sickle cell anemia, studies were conducted
using the hypomethylating agent, 5-azacytidine. Treatment of baboons, sickle cell anemia
patients (De Simone et al. 1982; Charache et al. 1983) and β-thalassemia patients (Ley et
al.1982) with 5-azacytidine successfully showed increases in HbF. Cytotoxicity and
myelosuppression, however, were a great concern as potential side effects when using this agent
(Ley et al. 1983). Decitabine, another demethylating agent, was also tried with better results and
less cytotoxicity (Musallam et al. 2013). Long-term trials testing this agent remain to be
conducted.
Paradoxically, it was later inferred that some of the positive effects of increased HbF seen
with the use of 5-azacytidine were due to its cytotoxicity. Hydroxyurea, another drug conferring
similar S-phase specific cytotoxicity was tested for HbF induction in monkeys with success
(Letvin et al. 1984). Hydroxyurea, a ribonucleotide reductase inhibitor, proved to be a successful
agent and is now the current treatment for sickle cell anemia. Although its therapeutic effect is
not entirely understood, a possible mechanism of action is the induction of stress erythropoiesis
(Mabaera et al. 2008). Despite hydroxyurea being a known inducer of HbF in patients, it has
variable effects and a large number of patients do not respond to hydroxyurea treatments
(Charache, et al. 1992; Steinberg et al. 1997; Ware et al. 2002). Another disadvantage of
hydroxyurea use is its inability to induce HbF in a pancellular manner (Platt et al. 1984). Not all

16

erythrocytes, therefore, are spared of polymer formation. This drug is also completely ineffective
in the treatment of β-thalassemia.
Since hydroxyurea has variable effects on sickle cell patients, attempts to find other
therapeutic drugs have been made with varying degrees of success. Short chain fatty acids,
including butyrate, have been shown to increase HbF expression in animal systems as well as in
patients with sickle cell anemia and β-thalassemia (Ginder et al. 1989; Perrine et al. 1993;
Weinberg et al. 2005). Although butyrate has antiproliferative effects, intermittent dosage is well
tolerated and shows sustained HbF induction (Atweh et al. 1999). Small molecules such as
vanillin were developed to inhibit HbS polymerization and appeared promising (Abraham et al.
1991), but later proved to be difficult to achieve high concentrations with low toxicity.
The standard treatment for β-thalassemia major is life-long transfusions. Continued
transfusions results in iron overload and iron deposit leading to organ damage. Chelation therapy
with parenteral deferroxamine has proved to reduce tissue iron deposit, therefore diminishing the
probability of iron overload (Giardina & Grady 2001). Parenteral administration of
deferroxamine and its potential side effects, however, have resulted in lower compliance
(Olivieri 1999). Transfusions also carry the risk of transfusion-transmitted infections.
Stem cell transplantation is the only curable treatment for both sickle cell anemia and βthalassemia. A 5-10% mortality rate, high cost, and the difficulty in finding suitable donors
makes this option difficult for some patients. Furthermore, stem cell transplantation has not been
successful in patients with extensive disease from β-thalassemia. β-thalassemia patients with
significant liver damage from iron overload usually experience higher rates of graft rejection (up
to 30%) (Lucarelli et al. 1996).
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The lack of effective treatments for these conditions has sparked efforts to find new ways
to treat these conditions. In order to find more effective and potentially less toxic targeted
strategies to induce HbF production, it is important to fully understand the molecular basis of
developmental repression of the fetal γ-globin gene.

IV. Regulation of γ-globin gene expression

A. The Locus Control Region (LCR)
There are numerous sequence elements that play a role in the regulation of β-type globin
genes, including cis-acting factors as well as trans-acting factors (Stamatoyannopoulos, 2005;
Sankaran, Xu & Orkin 2010; Ginder, Gnanapragasam & Mian 2008). An important cis-acting
factor that regulates the expression of β-globin genes is an upstream locus control region (LCR)
(Tuan et al. 1985, Forrester et al. 1986, Grosveld et al. 1987). The locus control region is an
enhancer-like region upstream of the β-locus. It consists of five DNase I hypersensitive sites that
are located 6-20kb upstream of the embryonic ε-globin gene. It was originally discovered by a
series of experiments searching for the presence of DNase I hypersensitive sites that were
necessary for the expression of β-locus genes (Tuan et al. 1985; Forrester et al. 1986). The
importance of this region was further confirmed by showing that only in the presence of the
LCR, transgenic mice bearing the human β-globin locus were able to express human β-type
globin genes at high levels (Grosveld et al. 1987). The DNase I hypersensitive sites found in the
LCR have different functions. Some act as insulators (Bell, West & Felsenfeld 2001; Li et al.
2001), while others act as activators (Navas et al. 1998).
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Earlier studies focusing on the role of the LCR on globin gene expression, led to two
non-exclusive theories about regulation of the genes located in the β-locus. The first was a
competition model suggesting expression of globin genes is determined by which gene is closer
to the LCR (chromosome looping). The second is an autonomous control model suggesting
regulation of gene expression is mostly through sequences located in each globin gene promoter
region as well as trans-acting factors regulating each promoter. The competition model was
determined by developing transgenic mice with β-type globin genes placed at different distances
from the LCR. When placed closer to the LCR relative to embryonic and fetal β-type globin
genes, the β-globin gene is activated at earlier stages compared to its normal time of activation,
while the γ-globin gene is silenced earlier in development when placed farther from the LCR
(Hanscombe et al. 1991). Overall, the ε-globin gene appears to be highly regulated by
autonomous control in definitive erythropoiesis (Raich et al. 1990, Dillon & Grosveld 1991), βglobin gene appears to be largely regulated by chromosome looping during definitive
erythropoiesis, and the γ-globin gene is regulated by both types of control (Tanimoto et al. 1999).
Aside from distance, copy number and orientation are also important in the regulation of β-type
globin genes by the LCR (Tanimoto et al. 1999).

B. BCL11A and Sox6
BCL11A (B cell lymphoma/leukemia 11A) is a zinc finger transcription factor that was
first identified as being a common retroviral integration site in murine myeloid leukemia leading
to high expression of this protein (Nakamura et al. 2000). Genome wide association studies
(GWAS) searching for correlations between single nucleotide polymorphism and increased HbF
levels first led to the discovery of BCL11A in relation to γ-globin regulation (Menzel et al.
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2007). Later studies confirmed BCL11A plays an essential role in hemoglobin switching, as
BCL11A conditional knockout mice crossed with transgenic mice bearing the human β-locus
show a delay in γ-to-β-globin gene switch between E14.5 and E18.5 in fetal liver cells (Sankaran
et al. 2009). Absence of BCL11A also shows amelioration of the sickle cell phenotype in young
adult mice (Xu et al. 2012). Despite the silencing delay of γ-globin expression during early life in
BCL11A KO mice, γ-globin gene expression drastically diminishes between E18.5 and 4-5
weeks of age (Esteghamat et al. 2013), suggesting BCL11A plays an important role in the
hemoglobin switch during ontogeny but a less prominent role during adult regulation of γ-globin
expression.
In order to understand the mechanism by which BCL11A regulates γ-globin gene
expression, BCL11A has been screened for potential binding partners. BCL11A interacts with
many proteins including MBD3/NuRD complex components, GATA-1, FOG-1 and LSD-1
(Sankaran et al. 2008; Xu et al. 2013). BCL11A binds to the β-globin locus at two sites, the
hypersensitive site HS3 and the intragenic region between γ- and δ-globin genes (Sankaran et al.
2008). With the help of Sox6, BCL11A also contributes to the β-locus chromosome looping
necessary for γ-globin gene silencing as shown by 3C assays (Xu et al. 2010). Although a
potential candidate as a target in the re-expression of γ-globin, absence of BCL11A has
devastating effects on other cell populations such as B-lymphocytes (Liu et al. 2003).
Sox6 is a member of the Sry-related high-mobility group (HMG) box transcription
factors. The sox family of transcription factors binds to the minor groove of the DNA and leads
to DNA looping (Ferrari et al. 1992; Connor et al. 1994). Sox6 deficient mice show prolonged
expression of murine εy-globin gene beyond the hemoglobin switch, since part of its function is
to bind to and negatively regulate the εy-globin promoter (Yi et al. 2006). In the human β-locus,
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Sox6 physically interacts with BCL11A and binds to several regions of the β-locus, most likely
contributing to chromosome looping (Xu et al. 2010) (Figure 6).

Figure 6. BCL11A regulates γ-globin expression through its interaction with the NuRD complex
and contributes to long-range chromosomal interactions through Sox6. BCL11A interacts with
Mi2/NuRD complex components as well as GATA-1 and FOG-1. Green dots represent Sox6
binding sites within the globin locus, while purple dots represent BCL11A binding sites.
Adapted from Xu et al. 2010.
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C. The KLFs
The Krüppel-like family of transcription factors (KLF) also plays an important role in the
regulation of mouse and human globin genes. Krüppel-like factors are a family of DNA binding
proteins, characterized by three Cys2 His2 zinc fingers, which bind to the consensus CACCC
motifs (Bieker 2001). KLF1 (formerly known is EKLF) was the first Krüppel-like factor to be
identified in erythroid cells (Miller & Bieker 1993). KLF1 plays a crucial role in erythroid
development, and knockout mice die at day E14.5 of severe anemia due to failed fetal liver
erythropoiesis (Perkins, Sharpe & Orkin et al. 1995; Perkins, Gaensler & Orkin et al. 1996).
KLF1 binds to the CACCC motif of the β-globin gene where it acts as an activator, and mutating
this motif results in β-thalassemia (Feng, Southwood & Bieker 1994). Recent studies have
discovered yet a new mechanism by which KLF1 regulates the globin locus. KLF1 binds to and
activates the BCL11A gene (Borg et al. 2010; Zhou et al. 2010), thereby indirectly inhibiting γglobin gene expression. Although mutations in the KLF1 DNA binding domain causing KLF1
haploinsufficiency have been associated with HPFH (Borg et al. 2010), KLF1 also regulates
other non-globin erythroid-specific genes. Thus, it is not surprising that other erythroid
conditions have been associated with mutations of this transcription factor. A dominant negative
mutation in the zinc finger domain of KLF1 has been associated with hereditary spherocytosis
and hemolytic anemia (Heruth et al. 2010; Siatecka et al. 2010).
KLF1 is a very dynamic protein and is able to act as a transcriptional activator as well as
a repressor (Bieker 2001). The different roles of KLF1 are tightly regulated by post-translational
modifications and interactions with different cofactors. One of these post-translational
modifications, SUMOylation at lysine 74, allows KLF1 to interact with Mi2β and act as a
transcriptional repressor in order to inhibit megakaryopoiesis (Siatecka et al. 2007).
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Given the high degree of homology in the KLF family of proteins, the study of KLF1 led
to the screen of more Krüppel-like factors for a potential role in the γ-globin gene regulation.
KLF2, 3, 4, 5, 8, 11, 12 and 13 are all expressed in erythroid cells (Zhang et al. 2005). Of these
factors, KLF2 plays an important activating role in mouse embryonic εy- and βh1-globin genes
as well as human embryonic genes (Basu et al. 2005). KLF1, in conjunction with KLF2,
regulates the expression of human embryonic ε- and human fetal γ-globin genes by binding to
their promoter regions in transgenic mice during embryogenesis (Alhashem et al. 2011).

D. TR2TR4 and LSD1
A Direct Repeat Erythroid Definitive (DRED) complex was originally proposed to
regulate the expression of human ε- γ-globin genes and murine εy- and βh1-globin genes through
binding to direct repeats in their respective proximal promoter regions (Tanimoto et al. 2000).
The direct repeats are analogous to binding sites for nonsteroidal nuclear receptors. DRED was
later characterized as a large complex containing orphan nuclear receptors TR2 and TR4.
Although mutations in the binding sites for this complex in βYAC transgenic mice caused a clear
de-repression of embryonic and fetal globin genes (Omori et al. 2005; Tanimoto et al. 2000),
studies attempted at understanding the mechanism of action of TR2/TR4 appeared paradoxical.
TR2/TR4 null mice crossed with mice bearing the human β-locus showed delayed silencing of εand γ-globin genes in fetal livers, but forced expression of these receptors also led to an increase
in γ-globin expression in definitive erythroid cells (Tanabe et al. 2007).
TR2/TR4 was found to interact with co-repressors such as DNA methyltransferase 1
(DNMT1), lysine-specific histone demethylase 1 (LSD1), as well as components of the
nucleosome remodeling and histone deacetylase (NuRD) complex Mi2 and HDAC1/2 (Cui et al.
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2011). In order to dissect the role of other proteins belonging to the DRED complex, recent
studies have focused on LSD1 and its role in globin gene regulation. LSD1, a flavin-dependent
monoamine oxidase, can demethylate mono- and di-methylated lysines, especially H3K4 (Shi et
al. 2004). Recent reports have shown a knockdown of LSD1 increases fetal hemoglobin in
human primary erythroid cells (Shi et al. 2013). Because nonselective monoamine oxidase
(MAO) inhibitors have been shown to inhibit LSD1 (Lee et al. 2006), the use of MAO inhibitors
to induce HbF was appealing as these drugs are FDA approved for the treatment of depression.
An irreversible monoamine oxidase inhibitor, tranylcypromine, was recently shown to induce
HbF expression on human primary erythroid cells (Shi et al. 2013). Although an FDA approved
drug, tranylcypromine it is not widely used due to its significant side effects. In 1964 it was
withdrawn from the market due to alarming side effects such as paradoxical hypertension and
intracranial bleeding, resulting in the death of several patients. It was later reintroduced in the
market with greater limitations for its use (Atchley 1964). Considering tranylcypromine only
induces HbF by a 2-fold, its positive effect may not compensate for the drug’s potential negative
side effects. Furthermore, recent reports have also shown that inhibiting LSD1 blocks erythroid
differentiation, which may inacuratly appear as increased levels of HbF in adult human primary
erythroid cells (Xu et al. 2013).

E. HBS1L and MYB
Genome wide association studies (GWAS) comparing populations with high vs. low HbF
also identified SNPs in the region between HBS1L and MYB genes located on chromosome 6
(Menzel et al. 2007; Thein et al. 2007; Lettre et al. 2008; Uda et al. 2008). Patients with elevated
HbF showed a decrease in the expression of both HBS1L and MYB, but only forced expression
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of MYB resulted in an inhibition of γ-globin gene expression in the human myelogenous
leukemia line K562 (Jiang et al. 2006). An older observation that patients with partial trisomy 13
show a delay in the hemoglobin switch (Huehns et al. 1964; Sankaran & Sapp 2012) was
recently connected to the regulation of MYB. High expression of two microRNAs located on
chromosome 13 (miR15a and miR16-1) is thought to be responsible for this mechanism
(Sankaran et al. 2011). miR15a and miR16-1 target MYB, and forced expression of these two
microRNAs have been shown to increase γ-globin gene expression (Sankaran et el 2011).
Recently, MYB was also shown to positively regulate BCL11A and KLF1 in human primary
erythroid cells (Suzuki et al. 2013).

F. GATA-1 and FOG-1
GATA-1 was one of the first factors identified as a regulator of globin gene expression. It
is a zinc finger protein involved in the regulation of many erythroid specific genes (Evans,
Reitman & Felsenfeld 1988; Pevny et al. 1991; Simon et al. 1992; Weiss, Keller & Orkin 1994;
Fujiwara et al. 1996). It binds to the β-globin locus (Evans & Felsenfeld 1989; Martin, Tsai &
Orkin 1989; Tsai et al. 1989), and facilitates chromosome looping of the β-locus (Vakoc et al.
2005). Furthermore, GATA-1 binds to the distal promoter region of the γ-globin gene (HarjuBaker et al. 2008), allowing recruitment of the nucleosome remodeling and histone deacetylase
(NuRD) complex in a FOG-1 dependent manner (Fox et al. 1998; Hong et al. 2005). This
contributes to γ-globin silencing in definitive erythropoiesis. Friend of GATA-1 (FOG-1) is a
hematopoietic specific zinc finger protein and an important co-factor of GATA-1. In fact, most
of the functions of GATA-1 depend on binding to FOG-1 (Tsang et al. 1997). Importantly, FOG1 acts as a cofactor for GATA-1 in both its activating and repressive roles (Letting et al. 2004).
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V. Epigenetics
Epigenetics involves the study of changes in gene expression that are not the result of a
change in the DNA sequence (Berger et al. 2009). Epigenetic changes include DNA methylation
and histone modifications, and they play an important role in developmental proceses such as
inactive X chromosome, genetic imprinting, silencing of certain developmental genes and cell
differentiation.

A. DNA methylation and hydroxymethylation
DNA methylation is a major form of epigenetic regulation in which cytosine residues are
covalently modified at palindromic CpGs at their 5-position carbon (Figure 7). This modification
is regulated by a family of DNA methyltransferase enzymes (DNMTs) which include DNMT1,
DNMT2, DNMT3a, DNMT3b and DNMT3L (Bestor et al. 1988; Cheng & Blumenthal 2008;
Yoder & Bestor 1998; Okano, Xie & Li 1998; Bestor 2000). DNMT1, the maintenance DNMT,
methylates hemimethylated DNA, and is therefore in charge of methylating daughter strands
during replication (Probst, Dunleavy & Almouzni 2009). DNMT3a and DNMT3b show a
preference for unmethylated DNA and perform de novo methylation (Okano et al. 1999). CpGs
throughout the genome are methylated at at rate of 60%-90% depending on the tissue (Ehrlich et
al. 1982), yet clusters of CpGs (CpG islands) found in promoter regions are usually
unmethylated. Methylation of CpG islands plays a regulatory role in a handful of genes during
development, and aberrant methylation of CpG islands of tumor suppressor genes is known to
contribute to cancer development (Gopalakrishnan, Van Emburgh & Robertson 2008).
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DNA methyltransferases
Demethylases

Figure 7. DNA methylation in humans. DNA methyltransferases covalently modify the 5-C of
cytosine by adding a methyl group. Adapted from Ginder, Gnanapragasam & Mian 2008.
Although originally discovered in 1972 (Penn et al. 1972), 5-hydroxymethylation was
recently recognized as another epigenetic mark (Kriaucionis & Heintz 2009; Tahiliani et al.
2009). The Tet family of proteins are 2-oxoglutarate (2OG)-dependent and Fe(II)-dependent
dioxygenases responsible for this DNA modification. Tet proteins can carry out oxidation
reactions requiring Fe(II) and 2 (OG) to convert 5-methylcytosine (5mC) into 5hydroxymethylcytosine (5hmC) (Ito et al. 2010). 5hmC is thought to be an intermediate for 5mC
demethylation (He et al. 2011; Ito et al. 2011; Guo et al. 2011; Inoue & Zhang 2011; Wossidlo et
al. 2011; Iqbal et al. 2011), but its ability to hinder binding of 5mC binding proteins (Valinluck
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suppressor genes in cancer.
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B. Methyl binding domain proteins
A largely conserved family of nuclear proteins, the methyl CpG binding domain (MBD)
proteins, are known to be “readers” of DNA methylation. The role of MBD proteins is to
translate DNA methylation into histone modifications by the recruitment of silencing complexes
(Figure 8) (Jaenisch & Bird, 2003; Wade 2001). This family of proteins is composed of 5 known
proteins, MeCP2, and methyl-binding domain proteins (MBD) 1-4. MeCP2 was the first protein
to be identified, followed by a complex originally named MeCP1 (Meehan et al. 1989; Lewis et
al. 1992). MeCP1 was later discovered to be either MBD2 or MBD3 along with a multisubunit
complex (Ng et al. 1999; Cross et al. 1997; Feng & Zhang 2001; Feng et al. 2002). Subsequently,
other MBD proteins were identified based on their common MBD domain (Hendrich & Bird
1998; Hendrich et al. 1999a). MeCP2 as well as MBD1-3 act as transcriptional repressors,
whereas MBD4 acts as a thymine DNA glycosylase (Hendrich et al. 1999b).

C. MBD2 and MBD3, similar proteins?
Aside from the structural resemblance of their methyl cytosine binding domains (MBD),
members of the MBD family of proteins differ significantly in their structures. MBD2 and
MBD3 are the exception, sharing ~71% homology (Hendrich & Bird 1998). Despite their
structural similarities, however, functional differences between MBD2 and MBD3 have become
apparent. Expression of MBD3 appears to be ubiquitous, as it is found in almost every mouse
tissue including embryonic stem cells. MBD2, on the other hand, is selectively expressed in
certain tissues such as spleen and testes (Hendrich & Bird 1998). The specificity of MBD2
binding to its target genes comes not only from its tissue-specific expression but also adjacent
base pairs surrounding the CpGs (Scarsdale et al. 2011). In contrast to MBD2 knockout mice,
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which are healthy and viable, MBD3 knockout mice are embryonic lethal (Hendrich, et al. 2001).
Although all MBD family members bind to methylated DNA, MBD3 appears to be the only
member that non-specifically binds to methylated or unmethylated DNA (Hendrich & Bird 1998;
Fraga et al. 2003). Recent studies have suggested a higher affinity of MBD3 for
hydroxymethylated DNA, although further data supporting this view will be necessary to draw
firm conclusions (Yildirim et al. 2011; Baubec et al. 2013).
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Figure 8. The role of DNA methylation in gene silencing. During development, a number of CpG
rich promoter regions are methylated by DNMT enzymes. DNA methylation hampers RNA Pol
II from8advancing.
DNA methylation
recuirts
domain
proteins such as
Figure
DNA methylation:
A) Methylalso
Cytosine
is methyl-binding
synthesized by DNA
methyl
MBD2, and (DNMT1,
silencing complexes
the NuRD
which in
turn alter
histone
transferases
3a and 3b) such
usingasSAM
acts ascomplex,
the methylation
donor.
Demthylases
modification
furtherB)preventing
gene expression.
Adapted from
Ginder, Gnanapragasam
are
still underpatterns
investigation.
The mechanism
of DNA methylation
mediated
& Mian 2008. silencing: The top strand represents a transcriptionaly active gene. The
transcriptional
bottom strand is methylated at the CpG residues by the action of DNA methyltransferases
(DNMT1, 3a and 3b). DNA methylation or the recruitment of methyl CpG binding
proteins can directly inhibit recrutiment of RNA polymerase and transcription factors. The
main mechanism of repression is by the recruitment of co-repressor complexes by the
methyl CpG binding proteins. These complexes contain histone deacetylases and
chromatin remodeling proteins. Adapted from (Ginder, Gnanapragasam & Mian 2008).
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D. Histone modifications
Histone proteins (H1, H2A, H2B and H3 and H4) function to package eukaryotic DNA
into nucleosomes (Luger & Richmond 1998; Kornberg & Lorch 1999). Histone modifications
are a dynamic system that allows for regulation of transcription. Histones undergo posttranslational modifications, which serve as a regulatory function to influence chromatin structure
and accessibility of DNA to transcription factors and other transciptional regulators (Li, Carey &
Workman 2007). N-tails from histones H3 and H4 protrude from the nucleosome, and can
undergo covalent post-translational modifications such as methylation, phosphorylation,
ubiquitination, sumoylation and acetylation (Strahl & Allis 2000). Of these modifications,
histone acetylation and methylation are perhaps the best studied. Trimethylation of H3K4,
H3K36 and H3K79 are associated with euchromatin and characteristic of transcriptional
activation. This is also true of histone acetylation. On the other hand, trimethylation of H3K9,
H3K27, and H4K20 have been associated with silenced genes. Histone deacetylation is also
associated with gene silencing. (Strahl & Allis 2000; Bartova et al. 2008).
This “histone code” of posttranslational modifications is then “read” by complexes which
affect gene regulation. This process is complex and involves a large number of
proteins/complexes involved in recognizing histone marks. (Yun et al. 2011). Histone binding
proteins can help translate this “histone code” by exerting different effects on transcription, DNA
repair and other processes (Figure 9).
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Figure 9. Histone post-translational modifications result in different readouts by recruiting
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E. Epigenetics and globin gene regulation
Epigenetic mechanisms including DNA methylation and histone modifications play an
important role in developmental γ-globin gene silencing (Singal et al. 1997; Hsu et al. 2007;
Mabaera et al. 2007; Forsberg et al. 2000; Gribnau et al. 2000). DNA methylation was first
shown to play a role in globin regulation by several studies in different species, where an inverse
correlation between DNA methylation and gene expression was found (Mavilio et al. 1983;
McGhee & Ginder 1979; Shen & Maniatis 1980; van der Ploeg & Flavell 1980). Further studies
demonstrated that treating both primates and patients with the demethylating agent 5-azacytidine
resulted in increased expression of embryonic and fetal hemoglobins (DeSimone et al. 1982;
Charache et al. 1983; Ley et al. 1982). Whether or not hydroxymethyl DNA plays a role in the
regulation of these genes remains to be determined.

F. The role of the MBD2/NuRD complex in globin gene switching
MBD2 is known to bind to densely methylated CpGs (Meehan et al. 1989) and mediate
the recruitment of a silencing complex (Nucleosome Remodeling and Histone Deacetylase
Complex, NuRD). NuRD complexes includes at least one copy of each of the proteins Mi2α and
–β, HDAC-1 and -2, MTA-1 and -2, RbAp46/48, and p66α and –β (Hendrich & Bird 1998;
Hendrich & Tweedie 2003; Feng & Zhang 2001) as depicted in Figure 10.
The first association between MBD2 and globin gene regulation came from studies in the
avian systems, where DNA methylation was shown to have an inverse correlation to gene
transcription (Burns, Glauber & Ginder 1988). Using nuclear extracts from avian primary
erythroid cells, studies showed the MBD2/NuRD complex binds to the methylated DNA
proximally transcribed region of the ρ-globin gene (the avian embryonic globin gene) (Singal et
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al. 2002). Further purification and characterization of this complex showed MBD2 but not
MBD3 was found in this complex (Kransdorf et al. 2006). These studies led to the first direct
evidence of the MBD2/NuRD complex binding to, and regulating β-type globin genes during
development.
Studies crossing MBD2 knockout mice with transgenic mice bearing a yeast artificial
chromosome with the human β-locus (βYAC) led to a ~20- to 40% increase in γ-globin gene
expression (Rupon et al. 2006). Likely due to the lack of CpG rich nature of the human β-locus,
MBD2 does not interact directly with the promoter region of the γ-globin gene, suggesting its
regulatory function on this locus is via an indirect mechanism (Rupon et al. 2006). MBD2 is also
an important regulator of ε-globin gene expression (Rupon et al. 2011).
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Figure 10. The MBD2/NuRD complex. Densely methylated DNA is able to recruit methylbinding domain protein 2 (MBD2) as well as the NuRD (MeCP1) complex. Mi2α/β confers the
chromatin remodeling function of the complex. MTA1/2 and p66α/β act as transcriptional
repressors. The histone deacetylase activity is mediated by HDAC1/2, and RbAp46/48 are
histone-binding proteins.
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The potential of MBD2 as a therapeutic target for β-thalassemia and sickle cell anemia
has led to many studies investigating its structure, ability to recognize methylated DNA, and
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G. The role of the MBD3/NuRD complex in globin gene switching
Methyl-CpG binding domain protein 3 (MBD3), in contrast to other members of the
MBD family, does not show a significantly higher binding affinity for methylated DNA
(Hendrich & Bird 1998; Fraga et al. 2003). Similarly to MBD2, MBD3 is associated with a
NuRD complex, although the MBD3/NuRD and MBD2/NuRD complexes have independent,
non-overlapping functions (Le Guezennec et al. 2006; Hendrich et al. 2001). With respect to
hemoglobin switching, the MBD3/NuRD complex has been shown to interact with and
negatively regulate the globin locus through the association with two important transcription
factors, GATA-1 and Friend of GATA-1 (FOG-1) (Rodriguez et al. 2005; Hong et al. 2005;
Harju-Baker et al. 2008). The GATA-1/FOG-1/NuRD complex negatively regulates γ-globin
gene expression in βYAC transgenic mice by binding to its distal promoter (Harju-Baker et al.
2008). Of note, FOG-1 has also been shown to co-localize with GATA-1 in genes that are both
positively as well as negatively regulated by GATA-1 (Wang et al. 2002; Letting et al. 2004; Pal
et al. 2004; Jing et al. 2008), suggesting that GATA-1/FOG-1/NuRD complexes can be context
dependent activators or repressors. Although the GATA-1/FOG-1/NuRD interactions have been
well characterized in the mouse system, they remain to be elucidated in humans. The majority of
the MBD3/NuRD complex components also associate with BCL11A in mouse erythroleukemia
cells, suggesting a link between the regulatory function of BCL11A and the MBD3/NuRD
complex (Xu et al. 2013).

H. The complexity of the hemoglobin switch
The developmental switch of fetal γ-globin to adult β-globin gene expression is
characterized by several layers of regulation, ranging from cis-acting regulatory factors such as
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the LCR to trans-acting factors such as transcription factors and epigenetics. The hemoglobin
switch appears to have several axes of regulation and some of the connecting links between
different regulatory branches, if any, remain to be elucidated (Figure 12). Of note, the
mechanisms behind γ-globin gene silencing during development may not completely parallel the
mechanisms behind γ-globin gene silencing during adulthood.
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Figure 12. Factors contributing to the hemoglobin switch. Depicted above
are some of the factors that contribute to γ-globin gene silencing in adult
erythroid cells. Chromosome looping allows the locus control region (LCR)
to remain closer to β-globin gene. Sox6 along with BCL11A contribute to
chromatin looping. KLF1 positively regulates the β-globin gene as well as
BCL11A. MYB positively regulates KLF1 and BCL11A. The
MBD3/NuRD complex interacts with BCL11A and it also binds to the
distal promoter region of γ-globin via its interaction with GATA-1 and
FOG-1. The MBD2/NuRD complex negatively regulates the γ-globin in an
indirect fashion. Solid arrows indicate direct interactions, whereas dotted
arrows indicate indirect interactions.
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VI. Advances in techniques and animal models for the study of hemoglobin switching
In humans, the hemoglobin switch begins during development, and soon after birth γglobin chain synthesis is replaced by β-globin chain synthesis. In the adult bone marrow,
erythroid precursors also show elevated γ-globin expression that declines as cells differentiate
(Papayannopoulou, Brice & Stamatoyannopoulos 1976). Over the years, many systems have
been developed in order to study this complex process in vivo during development, and in vitro
by culturing hematopoietic progenitor cells. Each method has provided insights into this highly
regulated process, although proper regulation of globin genes has posed a challenge in all of the
systems.

A. Cell lines
Although a number of erythroleukemia cell lines have been useful in the study of
erythroid differentiation and γ-globin gene silencing, these lines have failed to show normal
expression of the β-type globin genes. The most commonly used human erythroleukemia cell
line is the brc-abl(+) chronic myelogenous leukemia line, K562 (Lozzio & Lozzio 1975). K562
cells are able to be differentiate into erythroid cells using the proper stimuli, but they display
high levels of γ-globin expression. The use of this particular cell line to find inducers of γ-globin
expression may therefore be misleading since basal γ-globin levels are higher than normal
human adult erythroid precursors. An adult mouse erythroleukemia line, MEL, has also been
used due to its ability to recapitulate erythroid differentitation (Friend et al. 1971). This cell line
expresses exclusively murine adult β-globins (βmaj and βmin) and no embryonic globin genes
(βh1 and εy). Different human globin constructs have been stably transfected into these cells in
order to study human globin regulation. However, γ-globin expression is not properly regulated
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in MEL cells (Skarpidi et al. 1998; Vassilopoulos et al. 1999). Even though erythroleukemia cell
lines have served as a good vehicle to study and understand erythroid differentiation, they are not
appropriate cell lines for finding targets to relieve γ-globin gene silencing in adult erythroid cells.
A new cell line was created in 2005 that resembles the adult hemoglobin expression
pattern. Chemical Inducer of Dimerization (CID) cells are bone marrow cells isolated from mice
bearing the human β-globin locus in a yeast artificial chromosome (βYAC). CID cells have been
stably transfected with the thrombopoietin receptor which, upon introduction of a commercially
available compound, is activated and signals these multipotential progenitor cells to differentiate
into megakaryocytic cells, erythroid cells, neutrophils and monocytes (Blau et al. 2005). This
cell line expresses high levels of murine alpha globin, which pairs with human β-globin to form
adult hemoglobin. γ-globin gene expression is low in CID cells, greatly resembling the pattern of
expression in human adult erythroid cells (Figure 13).
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CID-dependent !-YAC Bone Marrow Cells

FIGURE 1. A, human "-globin transcripts are detected in CID-dependent cells derived from 155-kb wild-type "-YAC transgenic mice, and CID-dependent cells derived
#117 Greek HPFH "-YAC transgenic mice exhibit HPFH. The autoradiograph shows results of RNase protection analysis. Sample sources are illustrated above the pan
indicate samples collected from more than one cell population or animal. Protected fragments are shown to the right of the panel; pBR322 MspI molecular mass markers (M
are shown to the left. #/(#$") quantitative values are the averages of two separately established cell populations; if more than two populations were analyzed, standar
are also shown. Hu ", human "-globin (205 bp); Hu #, human #-globin (170 bp); Mo $, mouse $-globin (128 bp); wt "-YAC, wild-type "-YAC transgenic mice; FL, fetal liv
B, fluorescent antibody staining of human #-globin protein chains in CID-dependent wild-type or #117 HPFH "-YAC BMCs. #-Globin chains are detected in #117 H
CID-dependent BMCs but not in wild-type "-YAC BMCs. Upper, non-transgenic BMCs. Middle, wild-type "-YAC BMCs. Lower, #117 HPFH "-YAC BMCs. Background sta
upper and middle panels is due to fixation and nonspecific staining with the secondary antibody. After background correction, 30% of the cells in the lower panel are
#-globin chain staining.

Figure 13. CID cells exhibit a human adult globin expression pattern. RNase protection assay
showing WT βYAC CID cells (highlighted by the box) expressing low levels of human γ-globin
(Hu γ) gene and high levels of human β-globin (Hu β) and mouse α-globin (Mo α). Adapted from
Blau et al. 2005.
GATCTCTGCCTCGTGTTGTCTGTTG-3! (forward), 5!-GATATA- paraformaldehyde/PBS, pH 7.2, for 1 h at 37 °C. After the add
TAGAAGATCTTTACCCTTGGCTCAGATGAA-3! (reverse); FKLF,
5!-GAAGATCTCCTGCACGATGCACACG-3! (forward), 5!-AGATCTAGGCAGAGGCTGGCAT-3! (reverse); and FGIF, 5!-GATACAATAAAGATCTATGGAAAAAGAAAAAGGAAA-3! (forward), 5!-GATATATAGAAGATCTTTAAGACTGAGGTGAAGAAT-3! (reverse).
The BglII sites are underlined. The 0.8-kb ApaI-HindIII gg1-VP64 fragment described above was made blunt-ended and ligated into BglII-cut,
blunt-ended, and phosphatased p!!LCR-" pr-BglII-" int2-enh. These
constructs were lipofected into CID-dependent wild-type "-YAC
BMCs as described above.
Characterization of AP20187-dependent Cells—Bone marrow- and
fetal liver-derived cells were expanded and harvested at various times
during culture for analysis of murine and human globin gene expression
by RNase protection (24), RT-PCR, or antibody staining (21) to detect
globin chains. For antibody staining, cells were washed with PBS in
15-ml conical tubes and then fixed in 1 ml of freshly prepared 5%
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ml of PBS/0.1% BSA (PBS/BSA), cells were centrifuged at 200
min, resuspended in 0.5 ml of methanol, and incubated at r
perature for 5 min. 10 ml of PBS/BSA were added; cells were ce
and washed once more in PBS/BSA. Cells were resuspended in
PBS/BSA containing 0.1% Triton X-100 (PBT) and incubated f
at room temperature with 1 !g of primary mouse anti-human
chain antibody (Cortex catalog number CR8115M1, San Lea
diluted in PBT. 10 ml of PBS/BSA were added, and cells we
fuged as above. This wash was repeated twice more. Cells w
pended in 100 !l of PBT and incubated with 100 !l of secon
rescein isothiocyanate-labeled goat anti-mouse IgG antibody
ImmunoResearch Laboratories, catalog number 115-095-1
Grove, PA) diluted 1:750 in PBT at room temperature for 30
were washed in the same manner as for the primary antibod
were resuspended in 50 !l of PBS; 5-!l aliquots were applied
Control samples were prepared similarly except that the fix on
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B. Stem cells
Mouse embryonic stem (ES) cells have served as a suitable way to study hemoglobin
switching. They can differentiate in vitro with the use of growth factors into erythroid cells, and
primitive cells can be clearly distinguished from definitive erythroid cells (Olsen, Stachuar &
Weiss 2006). Because erythropoiesis in the bone marrow takes place in a niche called
erythroblastic island, in which erythroblasts surround a single macrophage that contributes to
phagocytosis of the nuclei of erythroid cells (Bessis 1958), new culturing conditions have been
designed to recapitulate the bone marrow environment. Reports have shown co-culture of ES
cells along with stromal cells (OP9) help induce differentiation (Nakano 1996; Kitajima et al.
2003). The use of human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPS)
has also been of interest, as these could be used for mass production of hematopoietic
progenitors in vitro and have also been used to study erythroid differentiation and γ-globin gene
regulation. However, generating functional differentiated erythrocytes from hESCs and hiPS
cells poses a challenge in vitro, as they tend to exhibit embryonic-like behavior (expressing high
levels of embryonic globin genes). Co-culturing hESCs and hiPS cells with stromal cells has
allowed these cells to properly differentiatiate (Ma et al. 2008).
Attempts to use homogeneous, unilineage cells have led to recent advances by using
human progenitor cells (CD34+) from either neonatal blood or adult bone marrow. A two-phase
differentiation system allows high proliferation as well as synchronous differentiation of these
cells (Migliaccio et al. 2002). The use CD34+ cells has become standard in the studies of
hemoglobin switching. The major disadvantage of using stem cells for the study of globin gene
regulation is their low viability in culture. These cells are not viable past their differentiation
period.

43

C. Animal models
In an attempt to understand human β-type globin gene regulation in vivo, several
transgenic mouse models were created. Failed attempts to achieve high expression of human
globin genes in transgenic mice (Costantini et al. 1985; Townes et al. 1985; Kollias et al. 1986;
Chada, Magram & Costantini 1986) led to the discovery that flanking regions, particularly the 5’
DNase I hypersensitive sites, in the β-globin locus are important for the regulation of β-type
genes. The development of transgenic mice with the entire globin locus including its flanking
regions was then achieved (Behringer et al. 1990; Enver et al. 1990, Gaensler, Kitamura & Kan
1993; Peterson et al. 1993), and these mice successfully recapitulated the hemoglobin switch.
Because the mouse β-locus lacks fetal globin genes (it only contains embryonic and adult globin
genes), human γ-globin assumes the embryonic pattern of gene regulation in transgenic mice as
shown with dotted lines in Figure 1. The transgenic mouse model bearing the human β-locus and
its flanking regions in a yeast artificial chromosome (βYAC) has become the most widely used
among these mouse models (Peterson et al. 1993).
Meanwhile, several attempts were made at creating a sickle cell anemia mouse model by
using transgenic mice with human globin gene sequences including the β-globin mutation (Ryan
et al. 1990; Greaves et al. 1990; Trudel et al. 1991; Rubin et al. 1991; Fabry et al. 1992). Several
groups were successful at achieving cell sickling in these mice, but failed to recapitulate all of
the pathophysiology seen in sickle cell patients including organ damage. Further studies using
mice with additional mutations in the β-locus meant to increase polymerization showed sickling,
spleen and lung disease but also failed to recapitulate all of the clinical manifestations seen in
sickle cell patients (Trudel et al. 1994; Fabry et al. 1995). Thus, it became apparent that
endogenous murine globin genes were preventing the sickling required to mimic a full sickle cell
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BERK sickle cell disease mice show features similar to patients with sickle cell anemia
such as low hemoglobin, low hematocrit, and a high reticulocyte count (Paszty et al. 1997).
Some of the characteristic pathophysiology of sickle cell anemia such as large necrotic spleens,
microinfarcts in the liver and kidneys are also present in this mouse model.
A similar sickle cell disease mouse model was developed the same year using a construct
containing the LCR, the γ- and the mutated β-globin genes linked to a fragment containing the α1 globin gene (Ryan, Ciavatta & Townes 1997). This transgenic mouse model was crossed with
murine α- and β- knockout mice (Paszty et al. 1995; Ciavatta et al. 1995) in the same manner as
the BERK mice. Similar to the BERK mouse model, they express exclusively α- and βS- chains
as adults. This mouse model was also successful in recapitulating the sickle cell phenotype,
showing sickled cells in the peripheral blood, spleens characterized by vascular occlusions and
thrombosis, focal necrosis in the liver, and vascular occlusions in the kidney (Ryan, Ciavatta &
Townes 1997).
Although sickle cell anemia mice have offered a great model to study this condition in
vivo, they have one disadvantage. They express very low expression of HbF as adults (<1%),
which is lower than human adults with sickle cell anemia (2-8% HbF). Hence, in order to reach
the minimum HbF threshold necessary to observe amelioration of the sickle cell disease
phenotype, a higher level of γ-globin induction is necessary.
The use of baboons to study HbF synthesis began in the 1970s, when it was demonstrated
that baboons exposed to acute hemolytic stress as well as hypoxia showed an increase HbF
production (DeSimone, Biel & Heller 1978; DeSimone, Heller & Adams 1979). Baboons also
served as a good model to study the effects of 5-aza on HbF production (DeSimone et al.
1982).
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VII. Scope of this thesis
Our laboratory has previously shown the importance of the MBD2/NuRD complex in the
regulation of the β-globin locus genes. The work presented in Chapter 2 of this thesis details the
study of the in vivo effect of absence of MBD2 in the context of a humanized sickle cell anemia
mouse model. Importantly, the role of MBD2 in fetal hemoglobin regulation and its potential as
a target in sickle cell anemia is assessed in this model.
Two components of the MBD2/NuRD complex, MBD2 and p66α, play important roles in
the regulation of γ-globin gene expression (Rupon et al. 2006; Gnanapragasam et al. 2011). In an
attempt to explore the functions of other MBD2/NuRD components in γ-globin gene silencing,
we have investigated the role of Mi2β in the regulation of β-type globin genes in Chapter 3. The
independent function of Mi2β from the MBD2/NuRD complex and its dual function as a
repressor and an activator are explored in this chapter.
An insight into possible new therapeutic targets for hemoglobinopathies is also reviewed
in Chapter 4. Recent discoveries about γ-globin gene regulation have led to new potential ways
to treat β-type globin disorders such as sickle cell anemia and β-thalassemia. However, drug
development and delivery methods pose a challenge and will need to be accounted for when
considering such targets.
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VIII. Significance
Many factors contribute to the regulation of the developmental switch of fetal γ-globin
expression to the adult β-globin gene expression, including a locus control region, transcription
factors and epigenetics. The level of complexity of this process is augmented by the fact that γglobin gene regulation during development may not be completely analogous to the mechanism
involved in suppression of this gene during adulthood. Advances in understanding the regulation
of γ-globin gene expression will prove to be of upmost importance for patients with sickle cell
anemia and β-thalassemia, where an increase in HbF has clinical benefit. Given the complexity
and many pathways involved in the mechanisms behind silencing this gene, it is important to
find efficient ways to relieve γ-globin silencing in adult erythroid cells. Considering these
disorders are most prevalent in the developing world, the feasibility of drug delivery and
affordability of treatment should be considered when attempting to find ways to re-express γglobin expression as a potential therapy.
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Chapter 2: Absence of MBD2 ameliorates the phenotype of sickle cell mice.

I. Introduction
Sickle cell anemia is one of the most common single gene disorders worldwide, although
it is most prevalent in Africa, South America, the Caribbean, and the Mediterranean countries. It
is caused by a point mutation in the 6th position of the beta globin gene (A-to-T) that replaces a
glutamic acid for a valine (Ingram 1956). This mutation leads to reversible polymerization of the
affected hemoglobin (HbS) in deoxygenated states. These polymers injure the erythrocytes by
damaging the membrane cytoskeleton causing hemolytic anemia (Lux, John & Karnovsky 1976).
Furthermore, sickle-shaped erythrocytes cause a reduction in tissue perfusion by obstructing
capillaries and further adhesion to the vascular endothelium (Hebbel, Osarogiagbon & Kaul
2004).
Sickle cell disease is characterized by extravascular hemolysis (uptake and degradation of
erythrocytes by macrophages subsequently taken to the spleen), but a considerable amount of
intravascular hemolysis (rupture of cells within the circulation) also occurs. Free plasma
hemoglobin and arginase in the circulation affects the nitric oxide (NO) availability (Figure 15),
which reduces the vessels’ ability to vasodilate as well as to inhibit platelet activation (Steinberg
2009). It is well known that an increase in fetal hemoglobin (HbF) can ameliorate the phenotype
of sickle cell anemia by decreasing the amount of fiber formation (Nathan et al. 2003). Although
hydroxyurea, the current treatment for sickle cell anemia, is able to induce HbF, it has variable
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effects on patients (Charache et al. 1992; Steimberg et al. 1997; Ware et al. 2002). Current
efforts are focused on finding new, more efficient targets to increase fetal hemoglobin in these
patients. In order to conduct these studies, several transgenic mouse models that closely
recapitulate sickle cell anemia have been established (Ryan et al.1990; Greaves et al. 1990;
Trudel et al. 1991; Rubin et al. 1991; Fabry et al. 1992; Trudel et al. 1994; and Fabry et al.
1995).
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FIGURE 2. Intravascular hemolysis and NO bioactivity in sickle cell disease. Intravascular hemolysis releases hemoglobin, arginase,
and LDH into the plasma. Hemoglobin inactivates NO, generating methemoglobin and inert nitrate. The NO synthases generate NO
from the substrate L-arginine. Arginase consumes L-arginine. NO is also consumed by reactions with reactive oxygen species,
producing oxygen radicals like peroxynitrite (ONOO-)(C). Decreased NO bioactivity in sickle cell disease is associated with pulmonary
hypertension, priapism, leg ulceration, hypertension, and nonhemorrhagic stroke. (From Kato et al.[178].)

Figure 15. Intravascular hemolysis in sickle cell anemia leads to decreased nitric oxide (NO)
availability. Intravascular hemolysis leads to release of arginase and hemoglobin. (A) On one
end, hemoglobin inactivates NO, turning it into methemoglobin (metHb) and nitrate (NO3-). (B)
The released arginase also consumes L-Arginine, a substrate converted to NO by nitric oxide
This impairs the downstream homeostatic vascular functions of NO, such as inhibition of platelet
synthase
(NOS).and(C)aggregation
NO availability
is also decreased
bythe
reactions
with molecules,
reactive oxygen
activation,
and transcriptional
repression of
cell adhesion
VCAM- species.
1(vascular
adhesion molecule-1),
ICAM-1 (intercellular
adhesion
P-selectin, and priapism
EDecreased
NO cell
availability
leads to pulmonary
hypertension,
legmolecule-1),
ulcers, hypertension,
selectin.in patients with sickle cell disease. Adapted from Kato et al. 2007.
and strokes
NO bioavailability is also challenged by the depletion of arginine, the substrate for the NO synthases,
and by production of oxygen radicals via catalysis by hemoglobin and heme-causing superoxide-induced
NO consumption. Lysed erythrocytes liberate arginase that destroys arginine, furthering endothelial NO
deficiency[64,65,66,67,68,69]. For multiple reasons, hemoglobin sequestered in erythrocytes does not
cause NO depletion.
The aggregate effect of reduced NO bioavailability is to inhibit normal vasodilation and cause
endothelial activation and proliferation. Both hemolysis and loss of splenic function, which is a feature of
sickle cell anemia, are associated with red cell membrane damage with phosphatidylserine exposure,
activation of tissue factor, and thrombosis. Chronic anemia and tissue ischemia could also contribute to a
proliferative vasculopathy via activation of HIF1A (hypoxia inducible factor)–dependent factors like
NOS2A (inducible nitric oxide synthase), erythropoietin, and vascular endothelial growth factor.
Heme oxygenase (HMOX1) is an inducible enzyme that catabolizes heme and hemoglobin, and is
expressed in the endothelium. In sickle transgenic mice, heme oxygenase reduces vascular inflammation
and its induction inhibits reperfusion injury–induced stasis, leukocyte-endothelium interactions, and
adherence molecule expression. Its inhibition increases vascular stasis. While clearly effecting
vasoocclusion in sickle mice, the role of this enzyme in sickle vasoocclusion has yet to be reported in
patients[70]. One might hypothesize that individuals who express the highest heme oxygenase activity, or
have polymorphisms of HMOX1 that enhance its activity, could suffer fewer or milder vasoocclusive
episodes. The converse might also be true.
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The BERK mouse model is the most widely studied mouse model for sickle cell anemia
(Paszty et al. 1997). These mice contain three DNA fragments: a 6.5-kb miniLCR, a 1.5-kb
fragment containing the human α1-globin gene, and a 39-kb fragment containing the human fetal
and adult globin genes including the mutated sickle β-globin in place of wild type β-globin
(GγAγ,δ,βS). They also lack endogenous murine α-globin as well as endogenous adult β-globin
genes (βmaj and βmin). BERK mice express exclusively the human α and human βS genes with
minimal expression of HbF during adulthood (Paszty et al. 1997). The pathophysiology of the
BERK mice greatly resembles that of sickle cell anemia patients. It is characterized by hemolytic
anemia, low hematocrit and high reticulocyte counts. BERK mice also exhibit large necrotic
spleens (~13-fold larger than WT mice) and micro-infarcts in the liver and kidneys.
In humans, the gene responsible for producing the β-subunits of fetal hemoglobin, γglobin, is located on the β-globin locus on chromosome 11. This locus consists of a locus control
region and a tandem array of genes placed in the order they are expressed during gestation and
adulthood (LCR-ε-γGγA-δ-β) (Stamatoyannopoulos 2005; Sankaran, Xu & Orkin 2010). In
addition to the locus control region, other cis-acting factors, and trans-acting factors including
epigenetics play an important role in the regulation of the genes encompassing the β-globin
locus.
Regarding the role of epigenetics in β-type globin gene regulation, DNA methylation has
been inversely correlated with globin gene expression (Mavilio, et al. 1983; McGhee et al. 1979;
Shen, et al. 1980; van der Ploeg Cell & Flavell, 1980). The methyl-binding domain protein 2
(MBD2) is known to bind to densely methylated DNA and negatively regulate genes through its
interaction with the nucleosome remodeling and histone deacetylase (NuRD) complex (Meehan
et al. 1989; Hendrich & Bird 1998; Hendrich & Tweedie 2003; Feng & Zhang 2001). MBD2
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plays a significant role in the regulation of human fetal γ-globin gene expression (Kransdorf et
al. 2006; Rupon et al. 2006, Gnanapragasam et al. 2001). Transgenic mice bearing the human
beta locus (βYAC) crossed with MBD2 knockout mice show ~20-fold increase in γ-globin gene
expression (Rupon et al. 2006), making MBD2 a potential therapeutic target in sickle cell anemia
(Figure 16).

Figure 16. Absence of MBD2 leads to an increase in γ-globin gene expression in transgenic mice
bearing a human β-globin gene locus. (A) RNase protection assay showing a significant increase
in γ-globin expression in MBD2 knockout mice crossed with βYAC mice. Two lines of βYAC
mice (depicted in black and gray) were used showing similar results. WT mice treated with 5azacytidine also lead to a similar increase in γ-globin expression suggesting MBD2 acts via DNA
methylation. Adapted from Rupon, et al. 2006
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In addition to its role in γ-globin gene regulation, MBD2 binds to and silences methylated
promoter regions of the endothelial nitric oxide synthase (eNOS) and vascular endothelial
growth factor receptor 2 (VEGF-R2) genes. Likely due to this function, MBD2 knockout mice
are protected from hind-limb ischemia and endothelial cells are also protected from H2O2induced apoptosis (Rao et al. 2011). MBD2 could therefore play an important role in the
pathophysiology of sickle cell anemia via its regulation of endothelial genes involved in
ischemic injury. In this study, we sought out to determine whether absence of MBD2 could
confer amelioration of the phenotype seen in sickle cell disease (SCD) mice.

54

II. Methods

Mouse strains:
MBD2 knockout mice were a kind gift from Dr. Adrian Bird. These mice are currently in
a mixed genetic background (FVB/C57BL/6 BALB/C). MBD2 knockout mice are viable, and
overall healthy. The only phenotype reported is a mildly abnormal nurturing behavior in mothers
(Hendrich, et al. 2001). BERK sickle cell disease (SCD) mice were a kind gift from Dr. Ivo
Torres. This strain, termed Hbatm1Paz Hbbtm1Tow Tg(HBA-HBBs)41Paz/J, is available from
Jackson laboratories, and it has been well characterized and described in the literature (Paszty et
al. 1997). BERK mice are transgenic for a human β-locus containing three constructs: a 6.5-kb
miniLCR, a 1.5-kb human α1-globin gene, and 39-kb encompasing the human fetal and adult
globin genes including the mutated sickle β-globin in place of wild type β-globin (GγAγ,δ,βS).
Endogenous mouse adult globin genes have been knocked out. These mice recapitulate to a great
extent the phenotype seen in sickle cell anemia patients.

Mouse breeding and maintenance:
Sickle cell disease (SCD) mice were mated and checked for vaginal plugs after 24 hours.
Mice were weaned 20 days to 1 month after birth. At this time, mice were ear punched and the
tissue was incubated for 4-5 hours at 55°C in the following digestion buffer: 50mM KCl, 10mM
Tris at a pH of 8.5, 4mM MgCl2, 0.45% NP-40, and 0.45% Tween-20. Samples were boiled
twice for 10 minutes, followed each time by a rapid spin in a mini centrifuge. Digested samples
were then stored at -20°C until PCR reactions were carried out. SCD mice were fed a custom
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made diet high in folic acid (Harlan, cat # TD. 120486, which consists of diet 7012 + 22mg Folic
Acid)

Breeding Genotypes and abbreviations:

Genotype

Abbreviation

Wild Type Mice

WT

MBD2 knockout mice

MBD2-/-

Sickle cell disease (SCD) BERK mice
(contains wildtype MBD2)
Sickle cell disease (SCD) BERK mice crossed
with heterozygote MBD2 knockout mice
Sickle cell disease (SCD) BERK mice crossed
with homozygote MBD2 knockout mice

SCDMBD2+/+ or SCD control mice
SCDMBD2+/SCDMBD2-/-

Table 1. List of abbreviations used in figure legends throughout chapter 2

Experiment
Survival Rate
Globin RNA expression and
hemoglobin chain synthesis
Blood Smears
Spleen size, H&E stains and
histological grade scoring

Genotypes Used
SCDMBD2+/+
SCDMBD2+/SCDMBD2-/SCDMBD2+/+
SCDMBD2+/SCDMBD2-/SCDMBD2+/+
SCDMBD2-/WT
MBD2-/SCDMBD2+/+
SCDMBD2+/SCDMBD2-/-

Table 2. Mouse genotypes used for each experiment
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Note

WT or MBD2-/- mice do not
synthesize human globin
genes and therefore could not
be tested
Organs from WT and MBD2/- mice were collected and
considered normal controls for
comparison

Mice Screening:
Polymerase chain reaction samples included 0.5µM of each primer, 200µM dNTPs, 1
unit of Taq polymerase, >1µg template DNA, 2.5µL of 10X reaction buffer (Invitrogen), and
nuclease-free water totaling a 25µL reaction. The reaction was carried as follows: 94°C (3min),
40 cycles of 94°C (30s), 58°C (30s), 72°C (1min) according to Paszty et al. 1998. Primers used
are included in Table 3.

Complete blood count and high performance liquid chromatography (HPLC):
Prior to each experiment, a fresh solution of the anesthetic Avertin was prepared by
adding 10mL of tert-amyl alcohol (Fisher) to 10g of 2-2-2 Tribromoethanol (Sigma). A working
solution was then made by mixing 2.5mL of the above Avertin solution with 97.5mL of saline.
Mice were anesthetized with an intraperitoneal injection of Avertin at a concentration of
0.015ml/gm of body, and cardiac punctures were performed in order to collect ~500µL of blood.
The blood was transferred to 1mL dipotassium EDTA blood collection tubes (BD Microtainer)
and a drop was used for blood smears. Slides and blood samples were then taken to VCU
hematology for further Giemsa staining and HPLC hemoglobin fractionation.

Organ Collection:
Mice spleen, liver and kidneys were collected from sacrificed mice. Organs were first
rinsed in 1X PBS. Spleen weights were measured and all organs were placed on a 10%
formaldehyde/1XPBS solution. Samples were taken to the VCU Department of Pathology for
hematoxylin and eosin (H&E) staining.
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Organ pathology scoring:
Following H&E staining for each organ collected, Dr. David Williams (a certified
pathologist) blindly scored each slide. The scores range on a scale of 0-3, with 0 representing no
disease observed and 3 representing the highest grade of disease.

Primer Table
Murine MBD2
β-Geo Cassette
Murine α-globin
(Hba)
Murine α-globin
deletion
Murine β-globin
genes
Murine β-globin
genes deletion
Human β-globin
transgene

Forward
CCTCAGCTGGCAAGATACCT
GGTCAGGTCATGGATGAGC
AGA
AGTGGGCAGCTTCTAACTAT
GC
ATAGATGGGTAGCCATTTAG
ATTCC
TTAGGTGGTCTTAAAACTTT
TGTGG
AGATGTTTTTTTCACATTCTT
GAGC
GTATGGGAGAGGCTCCAACT
C

Reverse
GGGGGTCATTCCGGAGTCT
CGCGGATCATCGGTCAGACGATT
GTCCCAGCGCATACCTTG
CCGGGTTATAATTACCTCAGGTC
ACTGGCACAGAGCATTGTTATG
AATGCCTGCTCTTTACTGAAGG
TCTGCCCAAATCTTAGACAAAAC

Table 3. The table above incudes all the PCR primers used for mice screening.
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III. Results

A. Absence of MBD2 in sickle cell disease mice increases survival compared to control
sickle cell disease mice
The first difference noted while breeding MBD2 knockout mice with sickle cell disease
mice was the survival rate between knockouts and control groups. Sickle cell disease mice
(SCD) were noted to have small litters and females either took longer to impregnate or lost more
litters compared to WT mice. Additionally, sickle cell disease pregnant females often delivered
stillborn pups. In contrast to sickle cell disease mice (SCDMBD2+/+), SCD mice crossed with
MBD2 heterozygote or homozygote knockouts (SCDMBD2-/- and SCDMBD2+/-) appeared to
have an improvement in mating efficiency and delivered larger litters. In order to quantify our
observation, we calculated the survival rates of the groups in question by comparing observed vs.
expected values per group. To do this, we first calculated the observed number of desired
genotypes obtained (SCDMBD2+/+, SCDMBD2+/- or SCDMBD2/-) per total number of mice
in the litter (observed value). Only the mice that survived until at least 1 month of age, at the
time of screening, were included in the total number. This was followed by calculating the
probability of obtaining the desired genotype for each group (expected value). Comparing the
“observed” category of mice to the “expected” category for each group (SCDMBD2+/+,
SCDMBD2+/- and SCDMBD2-/-) allowed us to quantitatively compare experimental groups to
the control. In normal survival rates, the observed/expected ratio should approach 1. As
expected, table 4 shows that the only group that displayed a significant decrease in survival was
the sickle cell disease control group (SCDMBD2+/+). Although not statistically significant,
SCDMBD2+/- mice also show a slight decrease in survival rate with a 0.89 observed/expected
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ratio, suggesting 50% deficiency of MBD2 does not fully rescue sickle cell disease mice.
Overall, SCDMBD2-/- showed the greatest improvement in survival which was 5-fold higher
than SCDMBD2+/+, suggesting this genotype confers a survival advantage to this group.

Genotype

Observed/Expected

SCDMBD2+/+

Total # of mice obtained
per group
5

SCDMBD2+/-

14

0.89

SCDMBD2-/-

25

1.37

0.27*

Table 4. SCDMBD2-/- mice exhibit a higher survival rate at 1 month of age compared to control
sickle cell mice (SCDMBD2+/+). A Z-Test was performed after comparing the ratio of observed
number of desired mice (SCDMBD2+/+, SCDMBD2+/-, SCDMBD2-/-) in each litter to the
probability of obtaining the desired mice (SCDMBD2+/+, SCDMBD2+/-, SCDMBD2-/-) for
each mating. Observed mice only included mice of at least 1 month of age at the time of
screening, and the total number of mice obtained per group is listed. A minimum of 40 matings
per group were included in the study. The Z-Test was performed making the null hypothesis H0:
proportion = expected against an alternative hypothesis HA: proportion < expected. The null
hypothesis was rejected for SCDMBD2+/+. * signifies a p value < 0.001.

Genotype

# of mice alive vs.
total number of mice
(alive/total)

SCDMBD2+/+

5/7

% of genotyped
mice surviving from
1 month of age until
3 months of age
71.4%

SCDMBD2+/-

12/14

85.7%

SCDMBD2-/-

22/24

91.7%

Table 5. A greater number of SCDMBD2-/- mice survive to adulthood compared to
SCDMBD2+/- and SCDMBD2+/+ mice. Shown above are the percentage of mice that survived
beyond 1 month of age until the time of sacrifice for experimentation (3 to 5 months of age).
Although not significantly different by a chi square test, SCDMBD2-/- mice have the highest
(91.7%) survival compared to SCDMBD2+/- (85.7%) and SCDMBD2+/+ (71.4%). At least 7
mice per group were included in this study.
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Even though the critical survival stage for sickle cell mice has been reported to be within
the first few days of life (Ryan et al. 1997), when the lungs begin to supply oxygen to the body,
adult sickle cell mice are still at risk of dying from sickle cell disease-related complications. We
therefore calculated the percentage of mice that survived between 1 month of age and the time of
sacrifice for experimentation (2 to 5 months of age). SCDMBD2-/- mice show a 91.7% survival
compared to SCDMBD2+/- (85.7%) and SCDMBD2+/+ (71.4%) (Table 5).

B. Absence of MBD2 is able to induce γ-globin gene expression and results in higher HbF
production
We hypothesized that the increased survival of SCDMBD2-/- mice was due to increased
γ-globin gene expression leading to an increase in HbF. We tested the γ-globin mRNA amounts
in blood taken from 2-5 month old SCDMBD2+/+, SCDMBD2+/- and SCDMBD2-/- mice.
SCDMBD2-/- mice express ~15-20% γ-globin mRNA calculated as γ/(γ+β)-globin mRNA ratio,
compared to SCDMBD2+/+ mice which express ~0.8% γ/(γ+β)-globin (Figure 17A).
SCDMBD2+/- mice also show a slight increase in γ/(γ+β)-globin mRNA (1.71%), correlating
with the increased survival rate of this group (Figure 17A). In order to detect hemoglobin protein
levels, blood was analyzed by high performance liquid chromatography (HPLC). The HbF
percentage levels of both SCDMBD2+/+ and SCDMBD2+/- were found to be undetected,
whereas SCDMBD2-/- showed a ~4% HbF (Figure 17B). The discrepancy between γ/(γ+β)
values detected by qPCR vs. protein levels detected by HPLC could be a result of the high
sensitivity of qPCR and low sensitivity of HPLC (since low amounts of mRNA are detected by
qPCR but appear undetected by HPLC in Figures 17A vs. 17B).
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Interestingly, HbA2, which is composed of 2 δ-globin chains and 2 α-globin chains, is
significantly elevated in the SCDMBD2+/+ control mice compared to normal values seen in
SCDMBD2-/- mice (normal range = 1.2-3%) (Figure 17C). Since HbA2 is also known to be
protective against sickle cell anemia (Nagel et al.1979) this could be attributed to a selective
advantage, where only SCD control mice that express higher levels of HbA2 survive. Hence, we
are only able to test control SCD mice with elevated HbA2 levels. A slight elevation of HbA2 in
SCDMBD2+/- in combination with a slight increase in γ-globin gene expression (Figures 17A &
17C) most likely accounts for the increase in survival in this group.
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Figure 17. Absence of MBD2 results in an increase in γ-globin gene expression and HbF but no
increase in HbA2. (A) qPCR showing SCD mice crossed with MBD2KO mice express 15.55%
γ/(γ+β)-globin mRNA compared to 0.74% γ/(γ+β)-globin mRNA expression in control SCD
mice. Heterozygote SCDMBD2+/- mice also show a slightly elevated γ/(γ+β)-globin ratio (1.71)
(B) HPLC showing elevated HbF levels (~4.5%) in SCDMBD2-/- mice. SCDMBD2+/- and
SCDMBD2+/+ show undetected HbF levels by HPLC. (C) HPLC showing hemoglobin HbA2
was significantly elevated in SCDMBD2+/+ control mice compared to SCDMBD2-/- mice.
**signifies p <0.02 and *** signifies p < 0.001 according to the students t-test.
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C. Absence of MBD2 reduces the number of sickle cells in the peripheral blood of sickle cell
mice
A representative blood smear taken from peripheral blood of adult SCD control mice
shows sickle cells admixed with target red blood cells and a high amount of polychromatic cells
(Figure 18B). Although a representative blood smear taken from a SCDMBD2-/- mouse shows
less sickling (Figure 18C), peripheral blood still shows a significant amount of polychromasia,
suggesting a large number of immature red cells are found in the circulation (Figure 18C)
compared to WT mice (Figure 18A). In order to quantify the amount of sickling, the number of
sickle cells were counted in 10 different fields for each mouse blood smear. On average, WT
mice showed 0 sickle cells per field, SCDMBD2+/+ mice showed 1.9 cells per field, and
SCDMBD2-/- mice showed 1.1 sickle cells per field. This suggests a decrease in the amount of
sickle cells in SCDMBD2-/- mice compared to SCDMBD2+/+ control mice. Since only one
mouse per group has been tested thus far, a larger number of mice will be needed in order
determine if this effect is significantly different between SCDMBD2-/- and SCDMBD2+/+
control mice.
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A"

of sickle
No. of sickle
No. of No.
sickle
cells
per field
field
cells percells
fieldper

WT WT WT

0

0

B"

SCDMBD2+/+
SCDMBD2+/+
SCDMBD2+/+

0

1.9 1.9 1.9

C"

SCDMBD2-/SCDMBD2-/SCDMBD2-/-

1.1 1.1 1.1

Figure 18. Blood smears show a decrease in the number of sickle cells in SCDMBD2-/- mice
compared to SCDMBD2+/+ mice. Giemsa stain showing representative blood smears from (A)
WT (B) SCDMBD2+/+ and (C) SCDMBD2-/- mice. Arrows show sickle cells (black) and target
cells (blue), characteristic of sickle cell anemia (B). The large portion of polychromatophillic
cells (purple) is likely due to reticulocytosis (B & C). The numbers below represent number of
sickle cells counted per field in a total of 10 fields for each mouse.
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D. Absence of MBD2 does not result in a significant improvement of sickle cell disease
organ damage
Although SCDMBD2-/- showed a marked improvement in survival over SCD control
mice likely due to an increase in HbF, pathophysiology characteristic of sickle cell anemia is still
present in SCDMBD2-/- mice. In order to quantify the degree of organ damage observed in the
groups tested, spleen weights were measured, and degree of damage was determined by scoring
H&E stains from three different organs (spleen, liver and kidney). Due to increased extramedullary erythropoiesis in the spleen, sickle cell disease mice are characterized by having large
necrotic spleens, usually ranging from 10- to 15-fold larger in size than WT mice (Ryan et al.
1997). As shown in Figure 19A, SCDMBD2-/- and SCDMBD2+/- mice displayed large spleens,
about 15 fold larger by percentage of body weight than WT and MBD2-/- control mice. This
increase in spleen weight was no different than SCDMBD2+/+ control mice, suggesting a
decrease in MBD2 expression does not alter the amount of extra-medullary erythropoiesis seen
in sickle cell mice.
To further determine whether MBD2 knockout confers protection of organs by
decreasing sickling and protecting the endothelium, spleen, kidney and livers were dissected
from mice post-mortem and cross sections were stained by hematoxylin and eosin (H&E).
Following H&E staining, samples were scored on a histological grade scale ranging from 0-3,
where 0 represents normal histology and 3 represents extensive organ damage and necrosis. WT
and MBD2ko mice were used as controls and show 0 histological grade in all three organs
(Figure 19B). WT and MBD2 knockout animals do show a small amount of extra-medullary
erythropoiesis (EE) as marked with a 1 in the histological grading scale (Figure 19B). Regarding
organ damage, no significant difference was seen between control SCD mice compared to
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SCDMBD2+/- or SCDMBD2-/- mice. The most affected organ in these mice was the spleen,
with a histological grade of 3 in all three groups (SCDMBD2+/-, SCDMBD2-/- and
SCDMBD2+/+). Although not significantly different, a trend was observed in SCDMBD2-/mice, in which the kidneys were spared from damage compared to SCDMBD2+/+ kidneys.
However, the opposite trend was seen in the liver, where SCDMBD2-/- mice show greater liver
necrosis than control mice (Figure 19B). This could be due to the difference in the amount of
capillaries found in the kidney and the liver, although further studies will be necessary to
determine this.
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Figure 19. Absence of MBD2 in SCD mice does not result in a significant decrease in organ
damage when compared to SCD control mice. (A) Spleen weights were measured as a
percentage of body weight. Error bars represent at least three mice. (B) Histological grading
scales from 0 to 3 (0 represents no damage or no extra-medullary erythropoiesis (EE), and 3
represents most damage and highest amount of extra-medullary erythropoiesis). Error bars
represent at least three mice as shown in the legend. No significant difference was found between
the two experimental groups (SCDMBD2+/- SCDMBD2-/-) compared to sickle cell disease
control mice (SCDMBD2+/+) in any of the tested parameters. NS = no significant difference
between SCDMBD2+/+ control mice and SCDMBD2+/- and SCDMBD2-/- mice.
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Representative H&E slides from spleen, kidney and livers dissected from either
SCDMBD2+/+, SCDMBD2+/- and SCDMBD2-/- show extensive organ damage compared to
WT and MBD2-/- controls (Figure 20). As shown by the arrows in Figure 20, all three groups
(SCDMBD2+/+, SCDMBD2+/- and SCDMBD2-/-) show pathology characterized by ischemic
infarcts and necrosis in the liver, increased hemorrhage and extra-medullary erythropoiesis in the
spleen, and infarcts and coagulative necrosis in the kidneys compared to normal histology seen
in WT or MBD2-/- control groups.
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Figure 20 Absence of MBD2 does not fully correct organ disease characteristic of sickle cell
anemia. H&E slides showing spleen, liver and kidney taken from either healthy control mice
(WT, MBD2-/-), or SCDMBD2+/+, SCDMBD2+/- and SCDMBD2-/- mice. Arrows show organ
damage including: increased extra-medullary erythropoiesis, coagulative necrosis and
hemorrhage in the spleen, ischemic infarcts and coagulative necrosis in the liver, and infarcts and
coagulative necrosis in the kidneys as well as loss of glomeruli.
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IV. Discussion
The MBD2/NuRD complex has previously been shown to play an important role in the
silencing of γ-globin gene expression. Selectively binding to CpG rich DNA, MBD2 is
associated with the NuRD complex and exerts a negative regulatory function (Meehan et al.
1998; Hendrich & Tweedie 2003; Feng & Zhang, 2001). The MBD2/NuRD complex does not
bind to the γ-globin promoter region, but rather it indirectly plays a role in silencing this gene
(Rupon et al. 2006). MBD2 Knockout mice bearing a yeast artificial chromosome with the
human β-globin locus (βYAC) have a ~15-20-fold increase in the γ-globin gene expression
(Rupon et al. 2006). Importantly, MBD2 knockout mice have a minimal phenotype affecting
only maternal nurturing (Hendrich et al. 2001). This renders MBD2 a great candidate as a target
in sickle cell anemia.
The BERK sickle cell disease mouse model has served as a useful way of studying this
condition. BERK mice exhibit a typical phenotype characterized by sickle-shaped erythroid
cells, severe anemia and organ damage. The severity of their phenotype is perhaps greater than in
humans because they express significantly lower amounts of HbF (<1%) and exhibit a greater
amount of hemolytic anemia (Paszty et al. 1997).
In our studies we have shown that knocking out MBD2 in sickle cell disease (SCD) mice
results in an marked increase in survival rate (~5-fold) compared to control SCD mice. The
increase in survival is likely due to an increase in γ-globin gene expression leading to higher HbF
synthesis. This finding is consistent with studies reporting a decrease in mortality in sickle cell
anemia patients with elevated HbF (Platt et al. 1994).
Likely due to the lower basal expression of HbF in sickle cell mice (<1%), a large fold
increase in γ-globin production upon knocking out MBD2 is not sufficient to completely correct
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the pathophysiology associated with this condition. Spleen size and organ pathology show no
significant difference between SCDMBD2+/+ and SCDMBD2-/- mice. Although it is apparent
that absence of MBD2 does not render complete correction of the sickle cell phenotype, the lack
of a difference between the pathophysiology of SCDMBD2+/+ and SCDMBD2-/- mice may be
due in part to a survival selection in control SCDMBD2+/+ mice. Adult SCDMBD2+/+ mice
display increased HbA2, a phenotype that confers protection against sickling (Nagel et al.1979).
The lack of improvement of organ pathology in SCDMBD2-/- compared to
SCDMBD2+/+ control mice may be attributed to the lack of a linear relationship between
increased HbF and decreased morbidity. Instead, there is a threshold at which morbidity begins
to decline (Powars et al. 1984). It is likely that SCDMBD2-/- mice produce sufficient HbF to
decrease mortality, but they lack sufficient HbF to decrease complications and fully correct the
phenotype of this disease.
Although not statistically significant, a trend was seen in the pathology of the kidney,
where both SCDMBD2+/- and SCDMBD2-/- mice showed less severity of kidney disease
compared to SCDMBD2+/+ control mice. Because the absence of MBD2 is known to increase
expression of eNOS and thus improve reperfusion injuries in mice (Rao et al. 2011), it is possible
that reduced expression of MBD2 in sickle cell mice increases NO availability. This effect may
reduce damage to the kidney, an organ with an extensive number of capillaries. This effect was
not seen in the liver, which may reflect a difference in the amount of capillaries present in these
two organs. Further studies such as measuring eNOS levels in vessels from these organs will be
necessary to determine whether this is the case.
Another factor that can potentially explain the lack of improvement in morbidity of
SCDMBD2-/- mice is the transgene copy number. SCD mice can either have one or two copies
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of the transgene. Due to the lack of information shared by the investigators who created the
mouse model, the site of insertion is unknown. The lack of information on the transgene’s
flanking regions has made it difficult to determine whether each mouse contains one or two
copies of the transgene. Transgene copy number (1 vs. 2) could therefore play a role in the
severity of the phenotype seen in each mouse. An increase in the number of mice tested to
account for a possible bias in each group tested will be necessary.
Another possible reason the absence of MBD2 did not result in greater phenotype
improvement is the genetic background. Studies have shown genetic modifiers in different
genetic backgrounds can account for a difference in phenotype seen in mice. A clear example of
this was shown on a diabetes model, where the mutations for obesity (lepob) and diabetes (leprdb)
results in obesity and mild diabetes in the C57BL/6 genetic background, whereas the same
genotype results in obesity and overt diabetes in the C57BLKS/J genetic background (Coleman
& Hummel 1973; Coleman, 1978). Genetic modifiers in different backgrounds must account for
different phenotypes. Given that MBD2 knockout mice are in a mixed genetic background
(FVB/C57BL/6 BALB/C), genetic modifiers could be contributing to the severity of the
phenotype. Other groups have shown a greater improvement in the SCD phenotype with a
similar increase in γ-globin expression in C57BL/6 mice (Xu et al. 2011). The mixed genetic
background of our mouse model could explain why the large fold induction of γ-globin gene
expression is insufficient to prevent disease progression in these mice. Studies on eNOS gene
regulation by MBD2 were also conducted in C57BL/6 mice (Rao et al. 2011). Hence, a pure
genetic background is needed to determine whether genetic modifiers affect the severity of the
SCD phenotype. SCD control mice that have selectively survived show an increased HbA2,
which is consistent with our hypothesis that a mixed genetic background has the potential to
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affect particular genes. Because the BERK mice are on a mixed genetic background, the higher
HbA2 levels could be associated with a particular genetic background.
Although further work will be necessary to determine the level of improvement in the
sickle cell phenotype in mice under a pure genetic background, the results obtained so far are
promising. Survival of SCD mice increases significantly when MBD2 is knocked out likely due
to an increase in HbF, and a decrease in the number of sickle cells seen in the periphery.
Furthermore, the limitations when studying sickle cell anemia in transgenic mouse models
suggests targeting MBD2 could be more beneficial in sickle cell anemia patients. Compared to
sickle cell anemia adult patients, BERK mice express much lower basal levels of HbF. The
significant fold induction of HbF seen in the SCDMBD2-/- mice compared to SCD control mice
could have a greater impact on the morbidity of sickle cell adult patients compared to transgenic
mouse models.
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Chapter 3: Mi2β-mediated silencing of the fetal γ-globin gene in adult erythroid cells

I. Introduction

Sickle cell anemia and β-thalassemia are two of the most common single gene disorders
worldwide. A need for a more effective treatment for these disorders has led to extensive studies
on the regulation of globin genes, since an increase in fetal hemoglobin (HbF) is known to be
beneficial for these patients. Hydroxyurea, currently part of the standard treatment for sickle cell
anemia, increases HbF levels in sickle cell patients but its effects are variable and it is not
effective in the treatment of most cases of β-thalassemia (Charache, et al 1992; Steinberg et al.
1997; Ware et al. 2002).
Development of effective and potentially less toxic targeted strategies to induce HbF
production will require full understanding of the molecular basis of developmental repression of
the fetal γ-globin gene. The γ-globin gene is located on chromosome 11 within the β-globin gene
locus. The β-locus consists of a locus control region followed by a group of five β-type globin
genes positioned in the order in which they are expressed during development (5’-LCR-ε-AγGγδ-β-3’) (Stamatoyannopoulos 2005; Thein & Menzel 2009; Sankaran, Xu & Orkin 2010). During
the embryonic stage of development, the ε-globin gene is expressed in the yolk sac, followed by
expression of the γ-globin gene in the fetal liver during most of gestation. At birth, γ-globin
expression declines as the expression of adult β-globin in bone marrow derived erythroid cells

75

predominates (Peschle et al. 1985; Ley et al. 1989). There are numerous trans-acting factors and
associated complexes involved in γ-globin gene silencing. These include BCL11A, KLF1/EKLF,
MBD2/NuRD, TR2/TR4, and GATA-1/FOG-1/NuRD (Sankaran, Xu & Orkin 2010; Ginder,
Gnanapragasam & Mian 2008). KLF1 (formerly known as EKLF) is a transcription factor
belonging to the family of the krüppel-like factors and it is critical in the expression of many
erythroid specific genes (Feng, Southwood & Bieker 1994; Perkins, Sharpe & Orkin 1995; Nuez
et al. 1995). It is C2H2 transcription factor that has a highly conserved DNA binding domain
(Bierker 2001). KLF1/EKLF binds directly to, and positively regulates the β-globin gene in adult
erythroid cells, whereas it negatively regulates the γ-globin gene indirectly through its role in
competition between the γ- and β-globin promoters for the LCR and through its binding to and
positive regulation of BCL11A, an important γ-globin gene silencer (Zhou et al. 2010; Borg et al.
2010) (Figure 21).
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EKLF regulates globin switching.

Siatecka M , and Bieker J J Blood 2011;118:2044-2054

Figure 21. KLF1/EKLF significantly contributes to the globin switch by directly regulating βglobin expression and indirectly regulating γ-globin gene expression via BCL11A. During the
embryonic/fetal stages KLF1 expression is low. This leads to lower expression of BCL11A and
therefore high expression of γ-globin. Low levels of KLF1 also lead to low expresssion of βglobin. This same effect is seen with KLF1 haploinsufficiency. In adult stages, KLF1 expression
levels increase, leading to higher expression levels of BCL11A, and therefore low γ-globin
expression. Higher KLF1 levels also lead to higher expression of β-globin gene via its role as an
activator. Adapted from Siatecka & Bieker 2011.
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Originally identified in a GWAS study (Menzel et al. 2007), BCL11A is a zinc finger
transcription factor that acts as a dominant negative regulator of the embryonic to adult
hemoglobin switch in murine development (Sankaran et al. 2009). It binds to the locus control
region (HS3) as well as an intergenic region of the β locus, between γ-globin and the δ-globin
regions (Sankaran et al. 2008). Absence of BCL11A during mice development results in a delay
of the switch from embryonic β-type globin genes into adult globin genes (Sankaran et al. 2010).
Knockout of BCL11A in humanized sickle cell transgenic mice greatly ameliorates their sickle
cell disease pheynotype (Xu et al. 2011). Of note, BCL11A plays an important role in the
regulation of B cells (Liu et al. 2003), and homozygous knockout mice are embryonic lethal (Liu
et al. 2003).
Epigenetic mechanisms, including DNA methylation and histone modifications, also play
an important role in developmental globin gene silencing (Singal et al. 1997; Pikaart, RecillasTarga & Felsenfeld 1998; Forsberg et al. 2000; Hsu et al. 2007; Mabaera et al. 2007), and
inhibitors of DNA methylation induce HbF levels in baboons and in humans (DeSimone et al.
1982; Ley et al. 1982; Charache et al. 1983). The MBD2/NuRD complex, which selectively
binds to methylated CpG-rich DNA, has been shown to play an important role in the silencing of
the human embryonic ε- and fetal γ-globin genes (Rupon et al. 2006; Gnanapragasam et al. 2011;
Rupon et al. 2011). NuRD co-repressor complexes include at least one copy of each of the
proteins Mi2α and –β, HDAC-1 and -2, MTA-1 and -2, RbAp46/48, and p66α and p66β
(Hendrich & Bird 1998; Feng & Zhang 2001). MBD2/NuRD does not appear to interact directly
with promoters of human β-type globin genes, suggesting that its silencing effects occur through
an indirect pathway (Rupon et al. 2006). The MBD3/NuRD complex, which is distinct from
MBD2/NuRD (Le Guezennec et al. 2006), directly interacts with and regulates genes within the
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β-globin locus through its association with the transcription factors GATA-1 and Friend of
GATA-1 (FOG-1) (Hong et al. 2005; Rodriguez et al. 2005). In βYAC transgenic mice, the
GATA-1/FOG-1/NuRD complex negatively regulates the γ-globin gene by binding to its distal
promoter (Harju-Baker et al. 2008). This complex is associated with positive regulation of the
adult β-globin gene (Miccio et al. 2010), suggesting that GATA-1/FOG-1/NuRD can act as
either an activator or repressor complex.
Mi2β (also known as CHD4) is the largest protein of the NuRD complex. It belongs to a
family of proteins called chromatin organization modifier (Chd), a member of the SNF2 family
of helicases (Eisen, Sweder & Hanawalt 1995), and confers the chromatin remodeling function
of the NuRD complex. Mi2β contains tandem plant zinc finger homeodomains (tPHD) and
tandem chromodomains (tCHD) (Woodage et al. 1997), which play an important role in
modulating its ATPase activity (Morra et al. 2012; Watson et al. 2012). It was recently shown
that the tandem PHDs are important for tCHD binding to dsDNA, and tPHDs also allow binding
to nucleosomes (Morra et al. 2012). PHDs specifically recognize histone H3 tails (Musselman et
al. 2012) (Figure 22).
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Figure 22. Mi2β (CHD4) binds to histone 3 (H3) tails through interactions with plant
homeodomains 1- and 2 (PHD1 and PHD2). Mi2β utilizes both PHD domains to recognize H3
histone tails. Adapted from Musselman et al. 2012
In addition to its negative regulatory role as part of the NuRD complex, Mi2β also acts as
a co-activator in lymphocytes (CD4) (Williams et al. 2004) by interacting with p300 and the E
box binding protein in the CD4 gene enhancer (Williams et al. 2004). Further evidence of its role
as both an activator and a repressor came from studies in T helper (Th2) cells. In these cells
Mi2β and GATA-3, can form either a repressive NuRD complex with HDAC activity, or an
independent activating complex with p300 (Hosokawa et al. 2013). The mechanism behind
Mi2β’s switch from a repressor to an activator remains to be elucidated.
Mi2β is highly expressed in tissues such as hematopoietic stem cells and in early
lymphoid, myeloid and erythroid precursors (Kim et al. 1999). Mi2β knockout mice are
embryonic lethal and conditional Mi2β knockout mice show a block in erythroid differentiation
at the proerythroblast stage (Yoshida et al. 2008). However, recent studies with conditional
knockout mice under an erythroid specific promoter have reported that a partial Mi2β knockout
is able to induce γ-globin gene expression without affecting erythoid differentiation (Costa et al.
2012).
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In this study we have explored a novel role of Mi2β in the hemoglobin switch. We show
here that Mi2β has an important role in the repression of γ-globin gene expression in mouse
hematopoietic cells containing a transgenic human β-globin locus, and in adult human primary
erythroid cells. While this repression is mediated in part by known negative regulatory activities
of Mi2β-containing NuRD complexes, a major part of the γ-globin gene silencing effect of Mi2β
is through direct positive regulation of the genes encoding the transcription factors KLF1/EKLF
and BCL11A.
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II. Methods

Cell Lines and Growing Conditions:
Chemical Inducer of Dimerization cells were a kind gift from Dr. Kenneth Peterson.
Cells were grown on IMDM supplemented with 10% heat inactivated fetal bovine serum (FBS)
and 2% Penicillin/Streptomycin. Cells were passaged at a concentration of 3-5 x 105 per mL
every 2-3 days. The B/B Homodimerizer (AP20187, Clontech) was added at a concentration of
0.1µM, and G418 at a concentration of 100-200µg/ml in every passage.

siRNA knockdown:
For each transfection group, 2.5 million CID cells at a density of 0.5 million cells/mL
were plated a day before transfection in a T25 flask. The following day, 5 mL of media were
placed on a T25 flask for each transfection group in order for the media to equilibrate.
Meanwhile, cells were counted, and 5 x 106 cells per group were spun at 100g for 10 minutes at
room temperature. Cells were then resuspended in 100µL/group of nucleofector solution
(provided by the nucleofector kit) and mixed well by gentle pipetting. 10µL of a 10µM QIAGEN
siRNA solution was placed in a sterile tube per group, and 5µg of GFP was used as control.
100µL of the mixture of cells and solution was added to each of the tubes containing the siRNA
in order to dilute the siRNA concentration to 1µM. CID cells were transferred to a cuvette
supplied by the nucleofector kit (#VCA-1003, Lonza) and pulsed in the D-012 setting of the
nucleofector machine (Amaxa, Nucleofector II). The cells were then transferred to the T25 flask
with equilibrated media and incubated at 37°C, 5% CO2. After a 24hr incubation period, the
control GFP sample was observed under the microscope to determine the transfection efficiency.
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RNA Isolation and qPCR:
RNA was isolated 72 hrs post-transfection by phenol-cholorform extractions (TRIzol,
Invitrogen) according to the manufacturer’s protocol. Samples were then subjected to DNase I
treatment as follows: 20µL reactions were made by adding 10µL of RNA at a concentration of
200ng/µL, 0.5µL of Dnase I (Ambion, at a concentration of 2U/µL), 0.5µL SUPERase Inhibitor
(Ambion, at a concentration of 20U/µL), 2µL of 10X Dnase Buffer (Ambion), and 7µL of DEPC
treated water. Samples were incubated at 37°C for 30min followed by 97°C for 10 min. 1µg of
RNA (5µL of above reaction) were then used for making cDNA in a 10µL reaction per sample
also including 0.5µL of RTase, 2µL of RT mix and 2.5µL of DEPC RNase free water from the
iScript cDNA synthesis kit (Bio Rad) according to the manufacturer’s protocol.
Gene expression was determined by performing qPCR, followed by analysis with the 2ΔΔCt

method. q-PCR was performed using either Power Sybr green PCR master mix (ABI) or

Taqman Fast Universal PCR master mix (ABI) in an ABIRT1900 instrument (1 cycle at 50°C for
2 min and 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min). Relative
quantification was determined using the SDS 1000 software. The primers used for q-PCR, listed
in Table 6, were designed to specifically bind to the cDNA of interest and not genomic DNA by
crossing exon-exon boundaries.

CD34+ cell isolation:
De-identified CD34+ cells were isolated from 10 mL apharesis packs donated by the
VCU bone marrow transplant unit. Cells were thawed quickly at 37°C in a water bath, and then
poured on a 50mL tube. Cells were then mixed with 1 volume of 1X PBS containing 2% FBS.
~30mL of volume of cells were added slowly to a 50mL tube containing 15mL of Ficoll-paque-
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plus (StemCell Technologies Inc #07907). The mix was spun at 400g for 30 minutes at room
temperature with no break. The middle layer containing the mononuclear cells was extracted and
placed on a fresh tube, where 40mL of 1X PBS with 2% FBS was subsequently added.
Mononuclear cells were then filtered through a 70µM nylon filter (BD Biosciences #352350),
and spun at 250g for 6 minutes at room temperature. The pellet was resuspended in 4-5mL of
DNase I solution (StemCell Technologies Inc. #07900) and incubated at room temperature for 15
minutes. Following DNase I incubation, 40mL of 1X PBS with 2% FBS and 1mM EDTA were
used to dilute the solution, followed by spinning the cells at 250g for 6 minutes at room
temperature. The cell pellet was re-suspended in 1X PBS with 2% FBS and 1mM EDTA at a
density of 2 x 108 cells/ml. EasySep kit (StemCell Technologies) was used for positive selection
of CD34+ cells according to the manufacturer’s protocol, and cells were subsequentely
maintained in growth medium consisting of StemSpan SFEM Medium with 1X CC100 cytokine
mix (StemCell Technologies Inc.), 40µg/mL of low density lipoprotein (Sigma) and 2%
Penicillin/Streptomycin.

Lentiviral Synthesis:
shMBD2 (GGGTAAACCAGACTTGAA) and shMi2β (#1:
CGGTGAGATCATCCTGTGTGATA, #2: GGACCTGAATGATGAGAAACAGA) sequences
were cloned into a pRRL.H1.shRNA vector. The vectors were then packaged into a lentivirus by
calcium phosphate transfections in 293T cells as follows: 6 million cells were evenly plated in
10mL of DMEM (Gibco) containing 20% FBS (Hyclone) media in a 10cm dish and incubated on
a 37°C, 5% CO2 incubator. The following day (at ~80% cell confluency) the medium was
removed and 9 mL of fresh media were added and incubated for 1-2 hours. Meanwhile, 3.75µg
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of PcmvR DNA (packaging plasmid), 1.5µg of PMD DNA (Envelop plasmid), 5µg of the
pRRL.H1 vector, and sterile dH2O totaling a 437µl solution were mixed in a 2mL tube and
vortexed. 63µl of 2M CaCl2 were then added drop wise. This 500µl solution was subsequently
added drop wise to 500µl of 2X HBS. The resulting 1mL solution was distributed evenly, and
drop-wise over the cells. After 5 minutes of incubation at room tempertature, cells were
transferred to a 37°C, 5% CO2 incubator. Following 16-18 hours of incubation, the media was
replaced with 9mL of fresh media and cells were once again placed in a 37°C, 5% CO2
incubator. After a 24hr incubation period, the media (now containing the virus) was collected in
a fresh tube and frozen quickly on dry ice, and later stored in -80°C.

Lentiviral Infection:
Three days following CD34+ isolation, 2 X 105 CD34+ cells per well were plated on a 12
well plate with 50µl of growth medium while the frozen virus stored at -80°C was thawed. Once
the cells were plated, 4µg/mL of polybrene were mixed with the lentiviral shRNA solution and
500 - 600µl of this solution were immediately added per well. The 12 well plates were incubated
at 37°C, 5% CO2 with slow shaking for 24hr. Growth medium was then added accordingly and
the cells were transferred to a regular incubator at 37°C, 5% CO2. On day 5 of incubation, GFP+
cells were selected by flow cytometry on a BD FACSAria™ II High-Speed Cell Sorter and
incubated on IMDM supplemented with 20% fetal bovine serum, 10ng/ml of SCF, 1u/ml EPO,
1ng/ml IL-3, 1µM Dexamethasone, 1µM Estradiol, and 2% Penicillin/Streptomycin for three
days. The cells were subsequently changed to a differentiation media consisting of IMDM
supplemented with 20% fetal bovine serum, 1u/ml EPO, 10ng/ml Insulin, and 2%
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Penicillin/Streptomycin and cultured for a period of 10 days. Cells were spun down and fresh
media was added every other day.

Fluorescence Activated Cell Sorting (FACS) on Human Adult Primary Erythroid Cells:
1 x 106 cells were washed on 10-12mL of 1XPBS/10%FBS buffer and spun at 300g for 5
minutes at room temperature. The cell pellet was then resuspended in 100µL of the same buffer
and incubated with 0.06µg of CD71 and 0.015µg CD235a for 20 minutes. Cells were then
washed twice with 1.5mL of buffer by spinning at 300g for 5 minutes and adding fresh buffer
each time. The cell pellet was subsequently re-suspended on 400µL of buffer. Samples were then
analyzed by flow cytometry in a BD FACSCanto™ II machine. Antibodies used include antihuman CD71 (eBioscience #17-0719-42) and anti-human CD235a (eBioscience #12-9987-82).

CD34+ cell High Performance Liquid Chromatography (HPLC):
10 million of the above sorted differentiated human erythroid cells from either control
shSCR group or shMi2β group were spun down at 300g for 5 minutes and cell pellets were taken
to VCU hematology for further lysing and HPLC hemoglobin variant testing.

Giemsa Staining Human Adult Primary Erythroid Cells:
FACS sorted differentiated cells were spun in a cytocentrifuge for 10 min at 1000 rpm
and subsequently stained with Giemsa.

Chromatin Immunoprecipitation assays (ChIP):
107 CID cells or CD34+ hematopoietic progenitor cells, the latter collected at day 2 of
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erythroid differentiation, were crosslinked using 2.0 mM ethylene glycol-bis(succinimidyl
succinate) (EGS) at room temperature for 30 min followed by formaldehyde for 10 min. ChIP
assays were then be performed using the Millipore (EZ-Magna ChIP) kit per manufator’s
protocol. Antibodies used at the concentration of 7µg include ChIP-grade Mi2β antibody
(Abcam ab70469) and Normal Mouse IgG (Millipore #12-371). qPCR was performed as
described above and primers used are listed in Table 6.

Co-Immunoprecipitation Assays:
10 million CID cells per group were collected and assays were carried out using Sigma’s
kit manufacturer’s protocol (SIGMA, FLAG Immunoprecitipation kit cat# FLAGIPT1). rProtein
G beads were purchased from Invitrogen (#15920-010). Prior to the experiment, the protein G
beads were washed 4 times by spinning down at 500g for 30 seconds at 4°C, discarding the
supernatant and adding equal volume of 1X washing buffer each time (40µL of beads were used
per reaction). 1mL of lysis buffer with protease inhibitors was added to each group, and samples
were vortexed and placed on a rotator for 30 minutes at 4°C. The samples were then spun down
at 1300g for 10 minutes at 4°C, and the supernatant was transferred to a new tube. Pre-clearing
was performed as follows: 40µL of protein-G beads were added to each 1mL of supernatant, and
samples were placed on a rotator for 2 hours. Samples were subsequently spun at 5000g for 30
seconds at 4°C. 30µL of supernatant were removed and stored in -80° as the input control. The
remaining supernatant was divided into 2 tubes (480µL each). One tube was incubated with 15µg
of MBD2 antibody (Santa Cruz) and the other was incubated with 15µg of normal goat IgG, and
both samples were placed on a rotator overnight at 4°C. The following morning, 40µL of protein
G beads were added to each sample and tubes were placed on a rotator for 2 hours at 4°C.
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Following incubation with rProtein G beads, samples were washed 5 times by spinning at 5000g
for 30 seconds 4°C, discarding the supernatant and adding 1mL of washing buffer each time.
Once the supernatant was discarded from the last wash, gel loading tips were used to remove the
excess liquid without disturbing the beads. 40µL of 2x western blot sample buffer was added to
each sample and 30µL of buffer was added to the input control. All samples were then boiled for
5 minutes, and subsequently cooled to room temperature. Samples were spun twice at 13000rpm
for 30 seconds at room temperature, each time using a gel-loading tip to transfer the supernatant
to a new tube to separate the supernatant from the rProtein G beads. The remaining supernatant
was then used for western blotting. Antibodies used for western blotting include MBD2 (Santa
Cruz sc-1244), p66α (Upstate #07-365), HDAC-2 (Millipore #05-814), RbAp48 (abcam
ab79416) and MTA-2 (Santa Cruz sc-28731)

Western Blotting:
Whole cell lysates were made on 4% SDS and briefly sonicated. Samples were then
mixed with 2x loading buffer containing beta-mercaptoethanol and 1% bromophenol blue, and
subsequently ran on a 10% SDS gel. The protein was transferred onto a PDVF membrane for 1
hour at 100V. The membrane was subsequently blocked for an hour in a blocking buffer
consisting of 1X PBST in 5% milk. This was followed by 1-hour incubation with 5-10µg of the
antibody of interest in 1X PBST in 5% milk. Three 5-minute washes with 1X PBST were carried
out, followed by a 45 minute incubation of secondary antibody in a blocking buffer solution. The
secondary antibody was removed by three, 5-minute washes, followed by incubation of the
membrane with either West Pico Chemiluminescence substrate or Supersignal West Dura
Extended duration substrate (Thermo Scienctific) according to the manufacturer’s protocol.
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Antibodies used include MBD2 (Santa Cruz sc-1244), CHD4/Mi2β (Abcam ab54603),
EKLF/KLF-1 (Abcam ab88417), FOG-1 (Santa Cruz sc-9361) and BCL11A (Abcam ab19487).

Western Blots from Mouse erythrocytes:
Hemolytic anemia was induced in both wild type and MBD2 knockout mice by treatment
with two intra-peritonial injections of 1-acetyl-2-phenylhydrazine (10 mg/ml; Sigma) at a dose of
0.4 mg/10g of body weight, 16 hours apart. In order to allow the spleen to become a prominent
site of extramedullary erythropoiesis, mice were sacrificed 5 days after the second injection. At
the time of sacrifice, the spleens were harvested and single cell suspensions were obtained by
gentle brushing. Whole cell lysates were then made according to the Western Blot protocol
described above.

89

Human γ-globin
Human β-globin
Murine Alpha Globin
Murine glycophorin A
Murine MBD2
Murine Mi2β
Murine Mi2α
Murine α-1- spectrin
Murine aminolevulinate
dehydratase (Alad)
Murine Ferrochelatase
Murine erythropoietin (EPO)
Receptor
Murine transferrin Receptor
Murine GATA-1
Murine glucose-6-phosphate
dehydrogenase (G6PD)
Murine uroporphyrinogen III
synthase
Murine α-globin
Murine cyclophilin A
Murine FOG-1
Human KLF1
Human γ promoter
Human Mi2β
Human BCL11A
Human BCL11A Promoter
Human GAPDH Promoter
Human KLF-1 Promoter

Forward
GTG GAA GAT GCT GGA
GGA GAA A
GCA AGG TGA ACG TGG
ATG AAG T
AAT ATG GAG CTG AAG
CCC TGG
GCC GAA TGA CAA AGA
AAA GTT CA
TTT GAC TTC AGG ACC
GGC AAG ATG
GAA CCA CAG GGA GTT
AAT GAG
GAT GAA GAC TTT GAT
GAG CGT
TTA GCA CCA CAT ACA
AAC AC
GAG TTC CCA AGG ATG
AAC AG
GCG AGG TGG TCA TTC
TGT TT
CCC AAG TTT GAG AGC
AAA GC
ATA AGC TTT GGG TGG
GAG GC
CTG GGA TCG CCT ACA
ACC TC
TCG AAA TTG TAG GGG
CAG CG
GCT GCC TCT TCT CTT
TCC GT
AAT ATG GAG CTG AAG
CCC TGG
GAG CTG TTT GCA GAC
AAA GTT C
TTC TGG TGG ACT GCT
ATA TGT G
GCA AGA GCT ACA CCA
AGA G
GCC TTG ACC AAT AGC
CTT GAC A
ATA AAG ATA AGC CAT
TGC CTC C
AAC CCC AGC ACT TAA
GCA AA
TCC TTC TTT CTA ACC
CGG CTC
TCC CCT TCC TGC AGA
CAG CTC C
GCC TGG GCC CCC ACC
TGA TA

Reverse
TGC CAT GTG CCT TGA
CTT TG
TAA CAG CAT CAG GAG
TGG ACA GA
ACA TCA AAG TGA GGG
AAG TAG GTC T
TCA ATA GAA CTC AAA
GGC ACA CTG T
ATT GCT CGG GTG GTT
CGT GAA TTT
CTT ATA GAG GGA GTA
GAG GAA GAC
ACA CAT AGG CCT TAA
ACT CCT
AAA CAT ATC CTT TCC
TCC CTG
CTC CTC TGC TAG GAA
TGC TC
ACT GGA CCA ACC TTG
GAC TG
TGC AGG CTA CAT GAC
TTT CG
CTT GCC GAG CAA GGC
TAA AC
CTG CCA CAA GGT CAA
GGC TA
CCA TTT AAC GCA AGA
GGG CG
TGC ATG CTT TCC ATG
GGG AT
ACA TCA AAG TGA GGG
AAG TAG GTC T
CCC TGG CAC ATG AAT
CCT GG
AAG ACG TCC TTG TTG
ATG AC
GTG TTT CCG GTA GTG GC

Probe
FAM/AGG CTC CTG GTT GTC
TAC CCA TGG ACC /BHQ
FAM/CA GGC TGC TGG TGG TCT
ACC CTT GGA CCC
FAMTTGACATCCAATCTCCTGA
GGGTGGTGA /BHQ

GAA ATG ACC CAT GGC
GTC TG
GAC ATA TGC CTT GAA
CTC TTT CTC
GGA GGT CAT GAT CCC
CTT CT
CTG CGC GCT CTC GTG
ATT AT
AGG GAG GGC AGC ATA
CCG GG
GAC TTG GCA CGA GCT
CCC CG

Table 6. The table above lists the primers used for all the experiments described in the methods
section.
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III. Results

A. Mi2β is an important developmental regulator of the human β-type globin genes and
acts partially independently from the MBD2/NuRD complex
To study the role of Mi2β in MBD2/NuRD mediated γ-globin gene silencing in adult
erythroid cells, gene knockdown was carried out in chemical inducer of dimerization (CID) cells.
These cells are hematopoietic precursor cells derived from adult mice bearing a yeast artificial
chromosome containing the complete human β-globin gene locus (βYAC). CID cells have been
stably transduced with a receptor which, upon introduction of a commercially available chemical
ligand, triggers a signal transduction pathway allowing them to differentiate into erythroid cells
that do not express the γ-globin gene (Blau et al. 2005). They display characteristics of adult
erythroid cells and express mainly the β-globin gene with minimal γ-globin gene expression
(Blau et al. 2005).
Transient siRNA-mediated knockdown of Mi2β in CID cells resulted in a very large
increase in expression of the γ-globin gene at 72-hours post-transfection (Figure 23A). This
effect is ~900-fold greater than with knockdown of MBD2 (Figure 23B) which contrasts with the
equivalent induction of γ-globin gene expression after knockdown of Mi2β, MBD2 and p66α for
24-hours (Gnanapragasam et al. 2011). This led to a detailed study of Mi2β and its role in β-type
globin gene regulation. Knockdown of Mi2β also resulted in a significant increase in human
embryonic ε-globin gene expression in CID cells (Figure 23C), although the increase is ~8-10fold less than for γ-globin RNA. As shown in Figure 23D, simultaneous knockdown of Mi2β and
MBD2 did not result in greater γ-globin gene expression than knockdown of Mi2β alone.
Knockdown of MBD3 does not affect the expression of the γ-globin gene in CID cells
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(Gnanapragasam et al. 2011). These data suggest that Mi2β silences the γ-globin gene in this cell
line partially independently of MBD2/NuRD and MBD3/NuRD complexes. While β-globin gene
expression is also induced by 30-fold following Mi2β knockdown, this effect is relatively small
compared to the effect seen for the ε- or γ-globin genes, which are induced 350-fold and >3000fold respectively when normalized to glycophorin A expression (Figures 23C and 23A). In order
to determine if Mi2β knockdown induces expression of other erythroid-specific genes, we
measured expression of the mouse α-1 spectrin, Ferrochelatase, Epo receptor and Alad genes, as
well as the transferrin, GATA-1, G6PD, and Uros genes. There was no significant increase in
expression of any of these genes (Figure 23E), nor of the mouse α- globin gene (Figure 24C)
after Mi2β knockdown. These results suggest that Mi2β knockdown preferentially induces
expression of the human γ- and ε-globin genes rather than promoting further erythroid
differentiation of CID cells.
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Expression of the endogenous mouse εy and βh1 globin genes was measured in CID cells
after Mi2β knockdown. As shown in Figure 24A & 24B, both genes are significantly
upregulated, suggesting that Mi2β plays a silencing role in both the murine and human β-globin
loci. Interestingly, upon Mi2β knockdown the murine εy gene is de-repressed to a much greater
extent than βh1 (>100- fold versus ~3-fold), an observation similar to the relative effect on the
human fetal and embryonic β-type globin genes, in which the γ-globin gene is up-regulated much
more than the ε-globin gene (>3000-fold versus ~350-fold). These data are also consistent with
the finding that the εy gene is activated later in murine erythroid development than βh1
(Kingsley et al. 2006) and thus is more analogous to the human γ-globin gene than is βh1. The
murine α-globin gene is not affected upon Mi2β knockdown, suggesting its effect is confined to
the β-globin locus (Figure 24C).
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Because both Mi2β and its isoform, Mi2α (CHD3), have been shown to be incorporated
into NuRD complexes (Tong et al. 1998; Wade et al. 1998; Zhang et al. 1998), we examined the
role of Mi2α in γ-globin gene silencing. The level of Mi2α/CHD3 RNA was found to be ~10-15fold lower than Mi2β RNA by qPCR, and knockdown of Mi2α had only a minor (~1.5-fold)
effect on γ-globin gene expression in CID cells (Figures 25A-B), suggesting that the great
majority of γ-globin gene silencing requires only the Mi2β (CHD4) isoform.
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Figure 25. Mi2α knockdown exerts only a small effect on γ-globin gene expression in CID cells.
(A) Western blot showing Mi2α protein level knockdown in CID cells. (B) qPCR data showing
Mi2α knockdown leads to a ~1.5-fold induction of γ-globin (hγ) gene expression and no
significant increase in β-globin (hβ) gene expression. **signifies p < 0.02 according to the
student’s t-test.

Figure S1
Mi2α knockdown exerts only a small effect on γ-globin gene expression in CID cells.
(A) Western blot showing Mi2α protein level knockdown in CID cells. (B) qPCR data
showing Mi2α knockdown leads to a ~1.4-fold induction of γ-globin (hγ) gene expression
and no significant increase in β-globin (hβ) gene expression. **signifies p < 0.02
according to the student’s t-test.
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Based on the observation that Mi2β knockdown had a larger effect on γ-globin
expression than did MBD2 knockdown, we explored the possibility that loss of Mi2β, the largest
component of the MBD2/NuRD complex, could lead to destabilization of the complex and
reduce the levels of other components, thereby creating a larger effect than loss of an individual
component. Western blot (Figure 26A) and MBD2 co-precipitation assays (Figure 26B-C) in
cells in which Mi2β was knocked down by ~80-90%, showed that other components of the
MBD2/NuRD complex are present in normal abundance and able to interact despite depletion of
Mi2β.
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Mi2β knockdown does not lead to destabilization of the MBD2/NuRD complex.
(A) Western blot showing MBD2/NuRD complex components 72 hours after knocking

Figure 26. Mi2β knockdown does not lead to destabilization of the MBD2/NuRD complex.
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B. Mi2β silences the γ-globin gene in human hematopoietic progenitor-derived primary
erythroid cells
To determine the role of Mi2β on γ-globin gene silencing in the context of primary adult
human erythroid cells, we stably knocked down Mi2β in CD34+ human hematopoietic
progenitor derived erythroid cells via lentivirus-mediated shRNA infection. Two different Mi2β
shRNA constructs were tested. Both resulted in increased γ-globin gene expression at day 10 of
erythroid differentiation, and the amount of increased γ-globin expression obtained was
proportional to the degree of knockdown of Mi2β (Figure 27A). Mi2β knockdown with construct
#2 resulted in a ~20-fold increase in γ/γ+β-globin mRNA expression compared to ~9-fold in the
case of MBD2 knockdown (Figures 27B and 27C). Of note, at day 10 of differentiation, the level
of γ/γ+β- globin gene expression is <1% in both untreated and scramble shRNA controls. High
performance liquid chromatography peformed in a representative experiment showed a HbF
level of 13.2% of total hemoglobin when Mi2β was knocked down by ~25-30% (Table 7).
Because complete absence of Mi2β in the bone marrow of mice results in a block in
erythroid differentiation at the pro-erythroblast stage (Yoshida et al. 2008), we sought to
determine whether or not a partial knockdown of this protein would interfere with erythroid
differentiation. Fluorescence-activated cell sorting using the transferrin receptor (CD71) and
Glycophorin A (CD235a) surface markers showed that after Mi2β knockdown, erythroid
differentiation proceeds similarly to scramble shRNA controls after 10 days of differentiation, as
shown in Figure 27D.
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Figure 27. Mi2β regulates the expression of the γ-globin gene in human primary erythroid cells.
CD34+ human hematopoietic progenitor cells were infected with lentivirus vectors harboring
shRNA either for scramble control, two different Mi2β constructs, or MBD2. (A) Knockdown
with shMi2β #1 leads to a 7.2-fold induction of γ-globin gene expression determined by qPCR.
Knockdown with shMi2β #2 leads to a ~20-fold increase in γ-globin expression and a slight
decrease in β-globin gene expression. Shown below are the Mi2β expression levels of each
construct that were determined before cells were differentiated. (B) Partial knockdown of Mi2β
(construct #2) leads to a 20-fold increase in γ/γ+β-globin gene expression. (C) Knockdown of
MBD2 leads to a 9-fold increase in expression of γ/γ+β-globin gene expression. (D) FACS
analysis showing erythroid differentiation of 81.1% of CD34+ progenitor cells in which Mi2β is
knocked down compared to 93.8% of scramble shRNA control cells and 92.9% of cells in which
MBD2 is knocked down. ± signifies standard deviations for at least three independent
experiments. Error bars represent the standard deviation of at least three independent
experiments. *signifies p<0.05 and **signifies p<0.02 according to the students t-test.
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shSCR
Procedure:
Hemoglobin A
Hemoglobin A2
Hemoglobin F
Mi2β"mRNA

Ref Range:
[95.0-99.0]
[1.2-3.0]
[0.0-2.0]

Units:

Ref Range:
[95.0-99.0]
[1.2-3.0]
[0.0-2.0]

Units:

%
%
%
%

95.6
3.1
1.3
100

%
%
%
%

84.8
2.0
13.2
74.8

shMi2β
Procedure:
Hemoglobin A
Hemoglobin A2
Hemoglobin F
Mi2β"mRNA

Table 7. Mi2β knockdown increases HbF levels in human primary erythroid cells. Results
obtained by high performance liquid chromatography assay carried out in the VCUHS CLIA
approved clinical hematology laboratory showing a >10-fold increase in HbF after Mi2β
knockdown (shMi2β) compared to scramble control (shSCR). qPCR assay showed the level of
knockdown in the shMi2β treated primary erythroid cells was ~25%.
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Interestingly, as erythroid differentiation proceeds, two distinct populations of cells were
observed by flow cytometry of both control and Mi2β-knockdown cell populations. The major
population was differentiated down the erythroid pathway and expressed both transferrin
receptor and Glycophorin A (Figure 28A, quadrant 2), while the minor population did not stain
for either (Figure 28A, quadrant 3). When analyzed by morphology, the minor population was
found to consist of normally differentiated myeloid cells (Figures 28D-F, Quadrant 3). The size
of this myeloid cell population varied among different patient-specific CD34+ progenitor
batches, suggesting that a variable fraction of CD34+ cells in each batch assayed was committed
to myeloid differentiation before exposure to erythroid differentiation medium. The percentage
of myeloid cells was generally higher in Mi2β knockdown samples but this was highly variable
across experiments and there was overlap with controls (Figure 28A).
The differentiated Mi2β knockdown erythroid cells in quadrant 2 were found to have
~40% Mi2β knockdown (Figure 28B) and a very high γ/γ+β-globin gene expression level (15% 45% γ-globin RNA) (Figure 27B). In contrast, the myeloid cells in quadrant 3 showed a much
higher Mi2β knockdown (~90%) (Figure 28C). Thus the difference may reflect more Lentiviral
Mi2β shRNA expression in the myeloid compartment, which could impart a slight growth
advantage. Overall, these results show that partial Mi2β knockdown does not inhibit terminal
erythroid differentiation. These results differ sharply from the effect of conditional knockout of
Mi2β in murine hematopoietic cells in which there is a complete block in erythroid
differentiation at the proerythroblast stage (Yoshida et al. 2008).

104

A"

CD71%

shSCR'

shMBD2'

shMi2β'

81.1'±'28.4'

93.8'±'19.2'

5.5'±'5.2'

15.8'±'23.8'

4.1'±'3.9'

CD235a

120

C"

Quadrant 2

Mi2β/GAPDH RNA

Mi2β/GADH RNA

B"

100
80
60
40
20
0
shSCR

D"

shSCR Quadrant 2 (Q2)

Quadrant 3

120
100
80
60
40
20
0

shMi2β

shSCR

E"

shMi2β Quadrant 2 (Q2)

shMi2β

F"

shMBD2 Quadrant 2 (Q2)

20.0µm
20.0µm

shSCR Quadrant 3 (Q3)

shMi2β Quadrant 3 (Q3)

shMBD2 Quadrant 3 (Q3)

20.0µm

20.0µm

20.0µm

Figure 28. Higher Mi2β knockdown imparts a slight growth advantage to myeloid cells.
(A) FACS analysis showing erythroid differentiation of shSCR-, shMi2β-, and shMBD2-treated
CD34+ cells (B) qPCR analysis showing a ~40% knockdown level of Mi2β RNA in doublepositive cells taken at the end of differentiation (Quadrant 2). (C) qPCR analysis showing a 90%
knockdown of Mi2β RNA in double-negative cells taken at the end of differentiation (Quadrant
3). (D-F) Wright- Giemsa stain of scramble control, Mi2β knockdown and, MBD2 knockdown
cell populations. Photo micrographs were generated using an Olympus (Center Valley, PA)
BX41 compound microscope and Olympus DP71 digital camera at 100x magnification. Images
were acquired with Olympus DP Controller software.
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The level of Mi2β knockdown in cells found in quadrant 2 and quadrant 3 of Figure 28A is
consistent with the level of GFP expression from the lentiviral vector used to transfect Mi2β
shRNA (Figure 29). Lower levels of Mi2β knockdown (Figure 28B) correlate with lower GFP
expression levels (Figure 29B, magenta color). These double positive (CD71+CD235a+)
differentiated erythroid cells are also smaller in size compared to double negative (CD71CD235a-) cells (Figure 29A, magenta color). In contrast, the cells that were negative for CD71
and Glycophorin A were larger myeloid cells (Figure 29A, blue color) showing a much higher

B

FSC

A

FSC

Mi2β knockdown (~90%) (Figure 28C), and a higher GFP level (Figure 29B, blue color).

GFP
SSC

Figure 29. GFP expression in cells undergoing erythroid cell differentiation versus myeloid cell
differentiation. (A) Forward scatter vs. side scatter plots showing that differentiated erythroid
cells, depicted in magenta (Figure 28E, Quadrant 2), are smaller in size than cells lacking
erythroid markers depicted in blue (Figure 28E, Quadrant 3). (B) GFP expression levels showing
that the larger cells (blue) have higher GFP than differentiated erythroid cells (magenta).

Supplemental Figure 4
High level but not low level knockdown of Mi2β redirects erythroid cell differentiation to
106
myeloid cell

Interestingly, a small number of experiments showed a loss of Mi2β knockdown as the
cells approached terminal erythroid differentiation (Figure 30). Fluorescence-activated cell
sorting using CD71 and CD235a markers was conducted every 3-4 days of differentiation to
isolate erythroid cells, and Mi2β knockdown was determined by qPCR at each stage of
differentiation. A representative experiment shows the level of Mi2β knockdown decreases as
the cells progress through differentiation (Figure 30A). At day 12 of erythroid differentiation, the
same set of shMi2β-treated cells were tested for γ-globin gene expression and showed ~17%
γ/(γ+β)-globin RNA ratio when compared to shSCR (~0.01% γ/(γ+β)-globin) (Figure 30B). This
suggests Mi2β’s silencing effect on γ-globin gene expression occurs at early stages of
differentiation and Mi2β knockdown does not appear to be essential during the later stages of
differentiation to exert a significant effect. This event, however, did not occur in all experiments
conducted, and perhaps the level of knockdown at the start of differentiation determines whether
the cells are able to maintain a high level of Mi2β knockdown, or whether they are able to reexpress Mi2β.
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Figure 30. The silencing effect of Mi2β on γ-globin gene regulation occurs during earlier stages
of erythroid differentiation. (A). qPCR showing ~50% knockdown of Mi2β in CD34+ cells at
day 3 of growth medium (GM3), but higher level of Mi2β expression at days 6 and 12 of
differentiation (DM6 and DM12 respectively). Each value was normalized to shSCR controls on
each of the days the cells were tested. (B) qPCR showing ~17% γ/(γ+β)-globin mRNA
expression in shMi2β knockdown samples at day 12 of differentiation, compared to 0.01%
γ/(γ+β)-globin expression in shSCR sample control.
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C. Mi2β affects the levels of two important transcription factors involved in silencing
embryonic and fetal β-type globin gene expression, BCL11A and KLF1/EKLF
To further investigate the mechanism(s) through which Mi2β/CHD4 exerts such a large
effect on γ-globin gene silencing, we studied its effect on KLF1/EKLF and BCL11A, two
important regulators of γ-globin gene silencing. Knockdown of Mi2β in CID cells decreases both
KLF1/EKLF and BCL11A protein levels as shown by western blot (Figure 31A). Consistent
with the hypothesis that the silencing effect of Mi2β is at least partially independent from the
MBD2/NuRD complex, loss of MBD2 does not result in any decrease of KLF1 or BCL11A, in
either CID cells (Figure 31B), or in primary erythroid cells of βYAC containing MBD2 knockout
mice (Figure 31C). In fact, cells with MBD2 knockdown or knockout appear to express slightly
increased levels of BCL11A and KLF1 (Figures 31B and 31C).
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Figure 31. Mi2β positively regulates the expression of KLF1 and BCL11A in CID cells.
(A) Western blot showing a decrease in murine KLF1 and murine BCL11A protein levels after
Mi2β knockdown in CID cells. (B) Western blot showing no change in murine KLF1 and murine
BCL11A protein levels after MBD2 knockdown in CID cells. (C) Western blot showing no
change in murine KLF1 or murine BCL11A in primary adult mouse erythroblasts from MBD2
knockout mice.
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The effect of Mi2β knockdown on BCL11A and KLF1 expression was also observed in
CD34+ human hematopoietic progenitor derived erythroid cells, where Mi2β knockdown
downregulates both BCL11A and KLF1 mRNA and protein levels (Figure 32A & 32B
respectively). Likewise, MBD2 knockdown does not decrease expression of either KLF1 or
BCL11A in human primary erythroid cells (Figure 32C). Interestingly, these results suggest that
Mi2β acts as a positive regulator of the BCL11A and KLF1 genes in contrast to its negative
regulatory role as part of the MBD2/NuRD complex (Gananapragasam et al. 2011).
In order to investigate whether or not Mi2β directly activates the BCL11A and/or KLF1
genes through interactions at their promoter regions, we carried out chromatin
immunoprecipitation (ChIP) assays to examine occupancy of Mi2β in their proximal promoter
regions. As shown in Figure 33, Mi2β is significantly enriched at the proximal promoter region
of both the BCL11A and KLF1 genes in human primary erythroid cells. Thus Mi2β appears to
interact directly with and induce expression of both the BCL11A and KLF1 genes.
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Figure 32. Mi2β positively regulates the expression of KLF1 and BCL11A in human CD34+
hematopoietic progenitor derived primary erythroid cells.
(A) qPCR analysis showing mRNA levels of KLF1 and BCL11A following Mi2β knockdown
are decreased by 70% and 40% respectively. (B) Western blot showing a decrease in the levels
of BCL11A and KLF1 protein upon Mi2β knockdown in human primary erythroid cells. (C) The
mRNA levels of KLF1 and BCL11A following MBD2 knockdown are not affected. (D) Western
blot showing the level of MBD2 protein knockdown in human primary erythroid cells. Error bars
represent the standard deviation of three or more independent experiments. *signifies p < 0.05
and **signifies p <0.02 and *** signifies p < 0.001 according to the students t-test.
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Figure 33. Mi2β binds to BCL11A and KLF1 promoter regions in human primary erythroid
cells. Chromatin immunoprecipitation assay and subsequent qPCR showing significant
enrichment in the BCL11A and KLF1 promoter/exon 1 regions after 2 days of differentiation of
primary human erythroid cells. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used
as a negative control and enrichment values are normalized to IgG. Error bars represent the
standard deviation of at least three independent experiments. *signifies p<0.05.

In order to confirm Mi2β’s effect on γ-globin expression is partially through activation of
KLF1 expression, we co-transfected CID cells with siMi2β and a KLF1 expression vector. A 3fold over-expression of KLF1 24 hours post-transfection (Figure 34A) is able to diminish the
increase in γ-globin gene expression in siMi2β treated samples at 72hours post-transfection
compared to samples treated with siMi2β alone (Figure 34B). This confirms Mi2β acts, at least
partially, by activating KLF1.
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scramble control cells (siSCR) at 24 hours post-transfection. (B) qPCR data showing that
enforced KLF1 expression in Mi2β knockdown cells leads to a significant decrease in
γ/γ+β expression compared to Mi2β knockdown alone at 72 hours (62-fold induction vs.
89-fold induction). **signifies p < 0.02, and ***signifies p < 0.001 according to the
student’s t-test.
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D. Mi2β affects γ-globin gene expression in a manner largely independent of the FOG1/GATA-1/NuRD complex
Since GATA-1 and FOG-1 occupy the distal promoter region of the γ-globin gene and
play a repressive role on its expression through the NuRD complex in βYAC mice (Harju-Baker
et al. 2008), we explored the extent to which Mi2β acts through the FOG-1/GATA-1/NuRD
complex to exert its silencing effect on the γ-globin gene. Chromatin immunoprecipitation assays
in CID cells showed that Mi2β occupies the γ-globin gene promoter region in CID cells as shown
in Figure 35A, consistent with reported results in βYAC transgenic mice (Bottardi et al. 2009).
To determine the relative extent to which the silencing effect of Mi2β is mediated through the
FOG-1/GATA-1/NuRD complex, FOG-1 was knocked down in CID cells. In contrast to the
effect of Mi2β knockdown, this resulted in only a very small (~3-fold) increase in γ-globin gene
expression (Compare Figure 35B to Figure 23A). This suggests that the strong silencing effect of
Mi2β is mediated only in small part by the FOG-1/GATA-1/NuRD complex. In order to
determine whether knockdown of Mi2β results in an additive or synergistic disruption of some
type of cooperative effect mediated by interaction between the MBD2/NuRD and GATA1/FOG-1/NuRD complexes, we simultaneously knocked down MBD2 and FOG-1 in CID cells.
Combined knockdown of these two proteins resulted in a ~7-fold induction of γ-globin mRNA,
which is much lower than with Mi2β knockdown and only slightly different than the effect of
MBD2 knockdown alone (Compare Figure 35C to Figure 23B).
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Figure 35. Mi2β occupies the γ-globin gene promoter and acts in a partially independent manner
from GATA-1/FOG-1/NuRD.
(A) ChIP assays showing significant Mi2β enrichment at the γ-globin promoter region in CID
cells. The mouse α-spectrin gene was used as a negative control. (B) qPCR results showing
knockdown of FOG-1 leads to a ~3-fold induction of the human γ- globin (hγ) and a ~2.5-fold
induction of the human β-globin (hβ) gene. (C) Simultaneous knockdown of MBD2 and FOG-1
leads to a ~7-fold induction of γ-globin and a ~3-fold induction of β-globin. (D) Western blot
showing both FOG-1 and MBD2 knockdown in CID cells. Error bars represent the standard
deviation of three or more experiments. *signifies p < 0.05 and **signifies p <0.02 according to
the students t-test.
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E. Mi2β affects γ-globin gene expression independently of other MBD3/NuRD complexes
Since Mi2β is part of both MBD2- and MBD3/NuRD complexes and it acts in part
through the GATA-1/FOG-1/NuRD complex to repress γ-globin expression, we tested the
hypothesis that Mi2β could be acting partially through an MBD3/NuRD complex. However,
significant knockdown of MBD3 in CID cells (Figure 36A, shown by MBD3 mRNA levels due
to a lack of an MBD3-specific antibody) shows no change in γ-globin expression and a slight but
significant increase in β-globin expression (Figure 36B). MBD3 knockdown also leads to no
change on KLF1 and BCL11A protein levels in contrast to Mi2β knockdown (Figure 36C). This
suggests the effect of Mi2β on these transcription factors is independent of both the MBD2- and
MBD3/NuRD complexes (Figure 36C). Simultaneous knockdown of both MBD2 and MBD3
show a significant increase in both γ-globin as well as β-globin gene expression in a similar
fashion than MBD2 knockdown alone (compare Figure 36D to Figure 23B). These data, along
with previous studies (Gnanapragasam et al. 2011), suggests MBD3 does not have an effect on γglobin expression, and Mi2β’s silencing of γ-globin is largely independent of the MBD3/NuRD
complex.
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Figure 36. Mi2β acts independently of the MBD3/NuRD complex to exert its effect in γ-globin
gene expression.
(A) qPCR showing ~90% MBD3 knockdown in CID cells 24 hours after siRNA transfection. (B)
qPCR showing knockdown of MBD3 does not affect the expression of γ-globin but leads to a
slight increase in the expression of β-globin gene. (C) Western blots showing no change in
BCL11A and KLF1 protein levels following MBD3 knockdown in CID cells. (D) qPCR showing
simultaneous knockdown of MBD2 and MBD3 leads to ~14-fold induction of γ-globin gene
expression and ~7-fold induction of β-globin expression.
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Figure 37. Working model of Mi2β-mediated developmental globin gene silencing through
multiple mechanisms. Mi2β is a critical component of the MBD2/NuRD complex which
regulates developmental globin gene silencing independently of BCL11A and KLF1-EKLF in an
indirect manner. Mi2β binds to the distal promoter region of the γ-globin gene as part of the
MBD3/NuRD/GATA-1/FOG-1 silencing complex. Mi2β binds to and activates expression of
BCL11A and KLF1/EKLF, which in turn silence γ-globin gene expression. Solid arrows
represent direct interactions and dotted arrows represent indirect interactions
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IV. Discussion

The developmental switch from the fetal γ-globin expression, to the adult β-globin gene
expression, is regulated by multiple factors including DNA methylation, transcription factors
such as KLF1, BCL11A, GATA-1, TR2/TR4 (Sankaran, Xu & Orkin 2010; Ginder,
Gnanapragasam & Mian 2008), and epigenetic modifiers such as the MBD2/NuRD complex
(Kransdorf et al. 2006; Rupon et al. 2006).
As one of the major components of the MBD2/NuRD complex, Mi2β plays a critical
functional role in this repression (Gnanapragasam et al. 2011). Disruption of the interaction
between the MBD2 and p66α coiled coil domains results in a displacement of both p66α and
Mi2β from the NuRD complex and leads to a significant de-repression of the γ-globin gene in
CID cells (Gnanapragasam et al. 2011). In this study, we have found a novel role for Mi2β,
which appears to be independent of its function in MBD2/NuRD and MBD3/NuRD complexes.
We observed that knockdown of Mi2β has a greater effect in de-repressing γ-globin gene
expression than does knockdown of MBD2 and MBD3. Although the GATA-1/FOG-1/NuRD
complex is not essential for silencing human γ-globin expression in transgenic βYAC bearing
adult erythroid cells (Miccio & Blobel 2010), it contributes to the silencing of the γ-globin gene
through a direct interaction of GATA-1 in the distal promoter region (Harju-Baker et al. 2008).
Here we show that knockdown of FOG-1 in CID cells induces a small increase in γ-globin gene
expression, in contrast to Mi2β knockdown. Further, combined MBD2 and FOG-1 knockdown
results in much less γ-globin gene induction than Mi2β knockdown alone. Given that knockdown
of MBD3 in CID cells does not lead to an increase in γ-globin gene expression (Figure 36B), a
major part of the silencing effect of Mi2β appears to be independent of both the MBD2/NuRD,
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and MBD3/NuRD complexes.
In this report we show that knockdown of Mi2β results in down regulation of both
BCL11A and KLF1/EKLF, which exert strong γ-globin gene silencing effects in transgenic
βYAC mice and primary human erythroid cells (Lee et al. 2000; Sankaran et al. 2008; Sankaran
et al. 2009; Xu et al. 2010; Zhou et al. 2010; Borg et al. 2010; Xu et al. 2011). The similar effect
of Mi2β knockdown in both murine CID cells and human primary erythroid cells shows that
Mi2β acts as an activator of the BCL11A and KLF1 genes in both murine and human
hematopoietic cells. As MBD2 knockdown results in slightly increased levels of BCL11A
expression, and MBD3 knockdown results in no change in either of these transcription factors,
these results confirm that Mi2β regulates the BCL11A and KLF1/EKLF genes independently of
the MBD2/NuRD and MBD3/NuRD complexes. Mi2β occupies the proximal promoter regions
of both BCL11A and KLF1, a result consistent with a direct positive regulatory effect.
Mi2β’s silencing effect in γ-globin regulation appears to be critical during the early
stages of CD34+ cell differentiation, since loss of Mi2β knockdown during the first 6 days of
culture allows a significant increase of γ-globin expression at day 12 of differentiation. These
data are consistent with the pattern of expression seen with BCL11A and KLF1, where the level
of expression of these two genes begins to increase during the early stages of differentiation (Xu
et al. 2010; Siatecka & Bieker 2011). Mi2β occupies the promoter regions of BCL11A and
KLF1 at day 2 of erythroid differentiation, and therefore low expression or absence of Mi2β
during the beginning stages of erythroid differentiation most likely diminishes the activating role
of Mi2β on BCL11A and KLF1, resulting in an increase in γ-globin expression. Other
mechanisms of action cannot be ruled out.
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The concept of Mi2β as a gene activator is supported by previous reports for the CD4
gene in T-cells (Williams et al. 2004), T helper 2 cell identity (Hosokawa et al. 2013) and the
adult β-globin gene in mice (Miccio & Blobel 2010). We have shown previously
(Gnanapragasam et al. 2011) as well as in this report (Figure 36B) that a partial knockdown of
MBD3 in CID cells has little effect on the expression of the γ-globin gene (Gnanapragasam et al.
2011). Therefore, it seems unlikely that the role of Mi2β as an activator of the BCL11A and
KLF1/EKLF genes is mediated through the GATA-1/FOG-1/NuRD or the MBD3/NuRD
complex.
How Mi2β switches its function from a repressor to an activator remains to be
determined. One possibility lies on post-translational modifications of Mi2β or its binding
partners. In drosophila, the Mi2β’s homologue (dMi2) is known to be a phosphoprotein in which
the ATPase activity is regulated via phosphorylation (Bouazoune & Bhrem 2005). In mice, other
transcription factors involved in globin gene regulation undergo post-translational modifications
allowing them to switch from transcriptional activators to repressors (Bierker 2001).
Interestingly, in addition to a marked increase in γ-globin and ε-globin expression after
Mi2β knockdown in CID cells, a small increase in β-globin RNA was observed, but expression
of no other tested erythroid-specific genes was increased (Figures 23E and 24C). Together these
results suggest that the silencing effect of Mi2β on erythroid-specific genes in CID cells may be
restricted to the β-globin locus. In contrast to the results in CID cells, we observed a decrease in
β-globin gene expression in primary human erythroid cells with ~50% Mi2β knockdown,
consistent with the predicted effect of decreased KLF1 expression.
Based on the results presented in this report in conjunction with the literature, we propose
a testable working model in which Mi2β acts through multiple pathways to silence γ-globin gene
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expression, as shown in Figure 37. Mi2β is an important component of the MBD2/NuRD
complex which acts as a repressor of γ-globin expression in adult erythroid cells. It also is a
component of the GATA-1/FOG-1/MBD3/NuRD complex which binds upstream of the γ-globin
promoter region and exerts a negative regulatory effect. A third and previously unreported
function of Mi2β described here is through its positive regulation of the KLF1 and BCL11A
genes. In murine erythroid cells, the latter appears to be responsible for the great majority of the
silencing effect of Mi2β while in the primary human erythroid model this effect is less
pronounced. An intriguing observation is that knockdown of Mi2β by less than 50% in primary
erythroid cells exerts a large effect on γ-globin gene expression. This suggests that full γ-globin
gene silencing is dependent on maintaining a tightly controlled level of Mi2β.
There are a large number of potential molecular targets for therapeutically increasing
fetal hemoglobin levels in patients with β-globin gene disorders. In this report we focus on the
chromatin remodeling complex component, Mi2β, as a potential target. Chromatin remodeling
complexes could prove to be good targets for therapeutic induction of fetal hemoglobin
expression because even partial disruption of a complex component could affect expression of
multiple genes that are involved in γ-globin gene silencing. Indeed, Mi2β appears to silence γglobin gene expression through multiple pathways and, as shown in this report, its partial
depletion relieves silencing in human erythroid cells. Complete depletion of Mi2β might have
catastrophic consequences, through blocking erythroid differentiation, as shown in conditional
knockout mice (Yoshida et al. 2008). Knockdown of Mi2β in human primary erythroid cells at
times showed a loss of knockdown as differentiation proceeded. A possible reason behind this
finding is that cells with higher levels of Mi2β knockdown are detrimental for the cells, and
therefore cells develop ways to silence the lentiviral vector expression and regulate Mi2β
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expression. Consistent with a partial Mi2β knockdown sparing a block in erythroid
differentiation, a very recent report showed a partial Mi2β knockout in βYAC transgenic mice
resulted in increased γ-globin gene expression without adversely affecting erythropoiesis (Costa
et al. 2012). Since Mi2β exerts its chromatin remodeling and helicase functions through its
ATPase enzymatic activity, targeting its ATPase function is certainly appealing. Small molecules
capable of targeting the ATPase domain of Mi2β are a possible approach. Other possible targets
are Mi2β’s tPHD domains, which have been shown to be vital to the function of the ATPase
activity of this protein (Morra et al. 2012; Watson et al. 2012). As shown in Figure 22, disrupting
the interaction of the PHD domains with histone 3 tails could prove to be a successful target.
In summary, identifying specific epigenetic mechanisms of γ-globin gene silencing as
potential therapeutic targets seems promising. Indeed DNA methylation inhibitors and histone
deacetylase inhibitors induce embryonic/fetal globin gene expression and have shown clinical
efficacy (DeSimone et al. 1982; Ley et al. 1982; Ginder, Whitters & Pohlman 1984; Perrine et al.
1993). We have extended previous work that identified the chromatin remodeling protein, Mi2β,
as an important factor in developmental β-type globin gene silencing through its role in NuRD
complexes. Importantly, we show here that a major mechanism for its silencing effect is through
a direct positive regulation of KLF1/EKLF and BCL11A. The striking finding that as little as
50% reduction in Mi2β expression results in a large increase in γ-globin gene expression in
primary human erythroid cells suggests that it may serve as a useful molecular target for
therapeutic induction of HbF in patients with β-globin gene disorders.
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Chapter 4: Summary, Future Directions and Perspectives

Sickle cell anemia and β-thalassemia are among the most common single gene disorders
worldwide. Sickle cell anemia is characterized by abnormally “sickle” shaped red blood cells,
which cause vaso-occlusion and ischemia in small vessels leading to painful crises. Auto
infarction and necrosis of the spleen, kidney failure, strokes and acute chest syndrome are among
possible complications (Nathan et al. 2003). Hydroxyurea is the standard treatment for sickle cell
anemia but it has highly variable effects on patients (Charache, et al 1992; Steinberg et al. 1997;
Ware et al. 2002). The most severe form of β-thalassemia (β-thalassemia major) is caused by a
complete absence of expression of the β-globin gene and it is characterized by severe anemia.
The standard treatment for patients with β-thalassemia major is life-long transfusions. Iron
accumulation due to transfusions results in iron deposit in several organs, leading to damage
(Rund & Rachmilewitz 2005). Sickle cell anemia and β-thalassemia benefit from an increase in
fetal hemoglobin, which is composed of two fetal γ-globin and two α-globin chains.
Understanding the molecular mechanisms behind the silencing of γ-globin gene expression will
therefore prove to be important when attempting to develop new therapies for these conditions.
Advances in the field have led to a better understanding of the regulatory functions
leading to γ-globin gene silencing. Among the many regulatory mechanisms leading to this
process, DNA methylation is known to play a role in the regulation of embryonic and fetal
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globin gene expression (Mavilio et al. 1983; McGhee & Ginder 1979; Shen & Maniatis 1980;
van der Ploeg & Flavell 1980; DeSimone et al. 1982; Charache et al. 1983; Ley et al. 1982). The
methyl-CpG-binding domain protein 2 (MBD2), along with its remodeling complex (NuRD)
binds to and negatively regulates the ρ-globin gene in avian systems, and it indirectly regulates
the expression of γ-globin gene in humans (Singal et al. 2002; Kransdorf et al. 2006; Rupon et al.
2006; Gnanapragasam et al. 2011). Adult MBD2 knockout mice crossed bearing the human βlocus (βYAC) exhibit a significant increase in γ-globin gene expression (Rupon et al. 2006).
Among other important factors that regulate the expression of globin genes, KLF1 is a critical
regulator of the β-locus. KLF1 binds to, and positively regulates the expression of β-globin gene
as well as BCL11A (Zhou et al. 2010; Borg et al. 2010). BCL11A, a transcription factor known
to bind to the β-globin locus, plays a significant role in the regulation of γ-globin gene
expression (Sankaran et al. 2008; Sankaran et al. 2009; Xu et al. 2010). BCL11A knockout mice
show a delay in the γ- to β-globin switch (Sankaran et al. 2009), and crossing BCL11A KO mice
with sickle cell mice results in a drastic amelioration of the sickle cell disease phenotype (Xu et
al. 2011). The delay in γ-globin gene silencing seen in the BCL11A knockout mice early in life,
however, is not fully maintained through adulthood (Esteghama et al. 2013). This suggests
BCL11A plays a more significant role during the embryonic switch in mice, but further layers of
repression may play a role in silencing γ-globin expression throughout adulthood.
In the studies presented in Chapter 2, we investigated whether targeting MBD2 in vivo
could lead to amelioration of the sickle cell anemia phenotype in mice. Knocking out MBD2 in a
sickle cell anemia mouse model showed promising results by significantly increasing survival
compared to sickle cell disease (SCD) control mice. Blood smears of SCD mice crossed with
MBD2ko mice also showed a lower number of sickle cells present in the peripheral blood.
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Despite an increase in survival, some of the phenotype typical of sickle cell anemia including
splenomegaly, liver and kidney damage were still present in SCDMBD2-/- mice. Perhaps the
greatest disadvantage in using the BERK sickle cell mouse model is their low fetal hemoglobin
base line (less than 1%), which is significantly less than in adult humans with sickle cell anemia
(2-8%). A greater level of induction in γ-globin gene expression is therefore needed in order to
fully correct the symptoms of these mice. SCD mice also show a more severe phenotype
compared to sickle cell disease patients including greater liver necrosis and higher levels of
hemolytic anemia. In order to overcome this challenge, we will first determine whether genetic
modifiers play a role in the expression of γ-globin gene. The MBD2 KO mouse model used in
our laboratory is on a FVB/C57BL/6 BALB/C mixed genetic background. Because other studies
have reported higher baseline levels of γ-globin gene expression on BERK mice under a
C57BL/6 background (Xu et al, 2011), our approach will be to back-cross our mice at least three
generations into a ~90% C57BL/6 genetic background. Following the backcrosses, we will
measure HbF and harvest organs in order to determine whether there is a more drastic
improvement on the pathology of these mice. On the event that the genetic background does not
affect γ-globin gene expression, a different mouse model will be considered (Ryan et al. 1997).
Once in a pure genetic background, the role of MBD2 on endothelial nitric oxide
synthase (eNOS) will be investigated in BERK mice. MBD2 binds to, and negatively regulates
the expression of the eNOS gene. Absence of MBD2 in mice has been shown to confer
protection from hind-limb ischemic injury (Rao et al. 2011). Endothelial cells from large vessels
of SCDMBD2+/+ and SCDMBD2-/- mice will be tested for eNOS levels by
immunohistochemistry. Microcirculation studies will also be carried out to compare sickling and
blood flow in the two groups of mice. The effects of Mi2β on SCD mice will also be explored. In
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chapter 3, we have shown that ~50% Mi2β knockdown causes a significant increase in HbF
production without disrupting erythroid differentiation of human primary erythroid cells. In order
to determine whether Mi2β happloinsufficiency is able to ameliorate the symptoms of sickle cell
anemia, mice heterozygous for Mi2β will be crossed with BERK SCD mice. Similar experiments
will be conducted with this mouse model as shown in Chapter 2.
Given the limitations of the transgenic mouse models discussed in the introduction of this
thesis, there is a need for whole animal models in order to study human erythropoiesis. An
interesting study will therefore be to investigate the effects of knocking down MBD2 and/or
Mi2β in a “humanized” mouse model of hematopoiesis. Previous studies have shown that
stromal cells appear to regulate survival, migration and differentiation of hematopoietic stems
cells via transcription factors and cell cycle regulators (Dazzi et al. 2006). Osteoblasts in the
bone marrow also appear to play a role in hematopoiesis (Wilson & Trumpp 2006). This is
supported by the observation that CD34+ cells are not viable after differentiation in culture. A
more humanized in vivo model will allow us to determine whether the bone marrow environment
affects gene expression pattern and viability of these cells. This will be accomplished by the
engraftment of human hematopoietic progenitor cells treated with shMBD2 or shMi2β in the
bone marrow of immunocompromised mice. A tetracycline-inducible shRNA system will also be
used to control knockdown levels. The mouse strain NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, available
in the Jackson Laboratories, has a severe combined immune deficiency mutation (scid) and show
greater engraftment of human hematopoietic stem cells compared to other strains previously
studied. Aside from gene expression analysis to determine the effect of knocking down NuRD
complex components on γ-globin expression, we will also be able to determine any detrimental
effects of targeting NuRD complex components on the bone marrow in vivo. Prior studies with
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MBD2-/- mice have shown changes in Th1 and Th2 gene regulation (Hutchins et al. 2002), and
ablation of Mi2β hinders proper myeloid differentiation of mouse bone marrow cells (Yoshida et
al. 2008). In order to determine whether targeting MBD2 or Mi2β has detrimental effects in bone
marrow cells, myeloid markers will be used to monitor proper myeloid differentiation.
Further studies with the NOD/SCID mouse model will be conducted. CD34+ cells from
sickle cell anemia patients will be used instead of healthy donors in order to knockdown MBD2
or Mi2β and engraft them in NOD/SCID mice as described above. These experiments will allow
us to understand better whether targeting these proteins will alleviate the pathophysiologic
effects of sickle cell anemia in human cells in vivo.
In the studies presented in Chapter 3 we discovered a novel role for Mi2β, the chromatin
remodeling protein of the NuRD complex. In addition to its role as a negative regulator of γglobin gene expression through the MBD2/NuRD complex, Mi2β also acts as an activator of
BCL11A and KLF1, further contributing to the silencing effect on the γ-globin gene. It will be
important to confirm that Mi2β exerts its effect on γ-globin largely through its regulation of
KLF1 and BCL11A. In order to accomplish this, experiments with forced expression of BCL11A
and KLF1 in siMi2β-treated cells will be carried out to determine if the substantial increase in γglobin gene expression is diminished. Transient forced expression of KLF1 in siMi2β-treated
CID cells results in a partial decrease in γ-globin gene expression when compared to siMi2β
treated CID cells (Figure 34). Further experiments must be carried out with forced expression of
both KLF1 and BCL11A in CID cells as well as in human primary erythroid cells. In particular,
stable expression systems must be used in human primary erythroid cells in order to determine
the effect of over expressing KLF1 and BCL11A in shMi2β-treated cells. It is expected that
KLF1 and BCL11A mediate a large portion of the effect carried out by the knockdown of Mi2β,
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although the involvement of other factors in this process cannot be ruled out. In the event that
forced expression of KLF1 and BCL11A in a Mi2β knockdown setting does not ablate Mi2β’s
effect on γ-globin expression, the role of other factors acting through Mi2β will be investigated.
In order to do this, a microarray comparing WT primary human erythroid cells and shMi2β
treated cells will give rise to potential candidates. Erythroid-specific candidates will then be
investigated and validated.
The mechanism by which Mi2β acts as an activator rather than a repressor remains to be
determined. A plausible hypothesis is that the majority of Mi2β remains tightly bound to NuRD
complexes. A minor pool of free-floating Mi2β is able to interact with other proteins or cofactors that allow Mi2β to act as an activator. This idea is supported by experiments conducted in
CID cells showing that Mi2β knockdown does not affect the composition of the NuRD complex
(Figure 26). To further support this hypothesis, we will perform ChIP assays of other NuRD
complex components on the γ-globin or Ugt8 (a known target of the MBD2/NuRD complex)
promoter regions after Mi2β knockdown. This will allow us to determine if partial absence of
Mi2β affects other NuRD complex components’ ability to bind to these genes.
Post-translational modifications could also play a role in allowing Mi2β to change from a
repressor to an activator. In humans, Mi2β is known to be phosphorylated at Ser-1349 by the
kinase Ataxia telangiectasia mutated (ATM) following double strand breaks (Urquhart et al.
2011). In drosophila, dMi-2 has been shown to be a phosphoprotein, and its ATPase and
nucleosome remodeling activity are enhanced when phosphorylated. In order to test whether
post-translational modifications play a role in Mi2β’s activating/repressing role, we will first
look for potential post-translational modification consensus sites. In the case of phosphorylation,
kinase inhibitors could be used to block phosphorylation. Binding of Mi2β to the γ-globin
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promoter region (repressive role) as well as binding of Mi2β to BCL11A/KLF1 (activating role)
could then be measured to determine if binding affinity is affected. γ-globin and BCL11A/KLF1
gene expression can also be measured following the kinase inhibitor treatment to determine
potential changes. Ultimately, mapping other post-translational modifications could be achieved
by mass spectrometry.
Further studies will be carried out to investigate whether Mi2β interacts with other
partners in order to exert its effect as an activator. Recent studies have shown Mi2β interacts
with p300 and GATA-3 in Th2 T helper cells when acting as a transcriptional activator,
suggesting its ability to form complexes independently of the NuRD complex (Hokosawa et al.
2013). In order to determine whether or not Mi2β interacts with other NuRD complex
components while acting as an activator, ChIP assays will be conducted to test if other NuRD
complex components show enrichment in the BCL11A and/or KLF1 promoter regions. In the
event that no other NuRD components are present supporting the view of Mi2β acting
independently of the NuRD complex in its role as an activator, we will search for other potential
Mi2β binding factors. We will first conduct ChIP assays to determine enrichment of GATA
factors and p300 in the BCLL1A and KLF1 promoter regions since they are known to interact
with Mi2β in other systems. In order to investigate whether other factors also interact with Mi2β,
Mi2β will be tagged in order to conduct a tandem affinity purification (TAP) assay. Since Mi2β
interacts with the MBD2- and MBD3-NuRD complex, the proteins belonging to these complexes
will need to be pre-cleared by conducting consecutive immunoprecipitation reactions. The
purification product will then be subjected to mass spectrometry in order to identify potential
partners of Mi2β.
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In order to determine whether targeting Mi2β induces γ-globin gene expression in vivo,
we will screen for small molecules that will inhibit the ATPase catalytic domain of Mi2β. In
order to do this, the ATPase domain must be cloned in an expression vector and the expressed
domain must be purified. High throughput screening will then be carried out in which molecules
with favorable chemical properties such as solubility, decreased toxicity and stability are tested.
Potential small molecule candidates will be tested in vitro in human CD34+ hematopoietic
progenitor cells for effective inhibition of Mi2β. In the event we find a candidate(s) that
effectively inhibits Mi2β, leading to an increase in γ-globin expression without disrupting
erythroid differentiation in human primary erythoid cells, these molecules will be further tested
in sickle cell disease mice.

Perspectives:

Due to the need for more effective treatments for hemoglobinopathies such as sickle cell
anemia and β-thalassemia, there has been a long-standing search for understanding the molecular
mechanisms behind the fetal γ-globin gene silencing. The main challenges in finding a target to
successfully de-repress γ-globin expression in humans are 1) the complexity of how this locus is
regulated, in which many factors play a combinatorial effect on gene expression 2) finding
potential targets that will not have negative systemic effects 3) finding “targetable” proteins that
will provide easier ways for drug development and delivery.
The first challenge when attempting to find ways to relieve γ-globin silencing is the
complexity of its regulation. As reviewed in the introduction of this thesis, many layers of
repression lead to successful silencing of γ-globin gene expression. As it appears, many
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regulatory factors contribute to an overall global effect on the regulation of γ-globin gene
expression. In fact, individually knocking down several of these factors in human primary
erythroid cells appears to de-repress γ-globin gene expression in a similar manner (Xu et al.
2013). Finding a link between different branches of regulation is therefore imperative in order to
find a target that will have a therapeutic effect of a larger magnitude. Epigenetic mechanisms
offer the advantage of having broader effects, since epigenetic factors and their chromatin
remodeling functions regulate many genes. Our studies emphasize the role of the MBD2/NuRD
complex, which indirectly regulates γ-globin gene expression. Mi2β, a major component of the
NuRD complex contributes to the β-locus gene regulation through multiple pathways, including
its repressive functions via the GATA-1/FOG-1/MBD3/NuRD complex, the MBD2/NuRD
complex, its association with BCL11A, as well as its activating role in BCL11A and KLF1 gene
expression (shown in Figure 12). The role of Mi2β on γ-globin regulation through different
mechanisms makes this molecule a very promising therapeutic target.
The second challenge in finding potential therapeutic targets for β-globin disorders is
avoiding systemic detrimental effects. Two important transcription factors, BCL11A and KLF1,
are thought to play a particularly important role in the regulation of γ-globin expression.
BCL11A was shown to have a rather significant role in γ-globin gene silencing during mouse
embryogenesis (Sankaran et al. 2009). However, BCL11A is also an important factor in other
tissues and in regulating B-cell function (Liu et al. 2003). KLF1 is also known to play a
significant role in both β- and γ-globin expression but complete absence of this transcription
factor leads to β-thalassemia. Complete absence of KLF1 may also result in detrimental effects
in erythropoiesis, since KLF1 is important for the regulation of many erythroid-specific genes. In
fact, a dominant negative mutation in its zinc finger domain (“neonatal anemia” or nan) is known
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to cause hereditary spherocytosis characterized by hemolytic anemia (Heruth et al. 2010).
Targeting MBD2 offers the advantage of achieving an increase in γ-globin expression without
resulting in detrimental systemic effects. Apart from globin genes, MBD2 only regulates a small
group of genes such as murine IL-4 and gut genes (Hutchins et al. 2002; Berger et al. 2007).
Aside from a mild nurturing phenotype, MBD2 knockout mice appear to behave normally. We
have shown that Mi2β plays a significant role in γ-globin gene silencing, although a potential
disadvantage of targeting this protein is that complete absence of Mi2β can affect erythroid
differentiation, or other processes in tissues not included in this study. However, we have shown
that a partial Mi2β knockdown is able to increase γ-globin gene expression to a large extent
without affecting erythroid differentiation. The fact that complete absence of Mi2β is not
necessary to achieve an increase in HbF may prove to be beneficial, because it is difficult to
completely eliminate the expression of genes in an in vivo setting.
Another challenge in finding a potential new treatment for β-globin disorders is drug
development and delivery. As reviewed in the introduction of this thesis, a handful of
transcription factors play an important role in the repression of γ-globin but their lack of
enzymatic activity poses a challenge to find ways to target them. Using RNAi to target these
transcription factors through a lentiviral system is plausible. However, difficulties similar to the
ones encountered with gene therapy treatments attempted at introducing the β-globin gene in βthalassemia patients make this a difficult option. The vectors must be erythoid specific, and
prolonged expression is needed. Silencing of the integrated gene/RNAi sequence after an
extended period of time has been a long-standing challenge for gene therapy treatments. New
vectors have proved to be more efficient at stable expression and have shown success in patients
(Payen & Leboulch 2012), but long-term studies will be needed to assess this problem. The use
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of insulators and the integration of these genes within cellular promoters rather than using viral
promoters has decreased the risk of activating proto-oncogenes, yet insertion of these vectors in
intronic regions can lead to disruption of genes (Payen & Leboulch 2012). Although gene
therapy or the use of RNAi to target transcription factors may prove to be efficacious in the
treatment of β-thalassemia or sickle cell anemia, it may be difficult to bring such technology to
the developing world, in areas where this condition is most prevalent. The use of small
molecules has become an area of interest in the past few years. They have proved to be
successful in the treatment of cancer, and many small molecule drugs are already FDA approved
and a few are in clinical trials. Imatinib (Gleevec), a small molecule currently used for chronic
myelogenous leukemia is an example of such success (Fausel 2007). Because using an effective
small molecule could provide an easier delivery method (could be given orally), small molecules
may be an effective way to treat sickle cell anemia or β-thalassemia in the developing countries.
Considering Mi2β has an ATPase domain that could be targeted by a small molecule, it is a great
candidate as a possible therapeutic target for β-type globin gene disorders. MBD2 has a methylbinding domain (MBD), which could also be targeted by a small molecule. Although small
molecule inhibitors for DNA-protein interactions have been developed in the past (Ng et al.
2007), they are conventionally thought to be more difficult to target. A small peptide disrupting
the MBD2 interaction with other NuRD complex components may be a more effective way to
target this protein.
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